KR20230155310A - Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient - Google Patents
Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient Download PDFInfo
- Publication number
- KR20230155310A KR20230155310A KR1020220055057A KR20220055057A KR20230155310A KR 20230155310 A KR20230155310 A KR 20230155310A KR 1020220055057 A KR1020220055057 A KR 1020220055057A KR 20220055057 A KR20220055057 A KR 20220055057A KR 20230155310 A KR20230155310 A KR 20230155310A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- benzo
- oxo
- oxazin
- dihydro
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 55
- -1 N-hydroxypropenamide compound Chemical class 0.000 title claims abstract description 50
- 201000011510 cancer Diseases 0.000 title claims abstract description 47
- 239000004480 active ingredient Substances 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 22
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 3
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 201000006491 bone marrow cancer Diseases 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000006195 histone acetylation Effects 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 11
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000001093 anti-cancer Effects 0.000 abstract description 6
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical group C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 50
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 16
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 9
- 229940125801 compound 7f Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960005184 panobinostat Drugs 0.000 description 5
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- HQVFKSDWNYVAQD-UHFFFAOYSA-N n-hydroxyprop-2-enamide Chemical class ONC(=O)C=C HQVFKSDWNYVAQD-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 230000004668 G2/M phase Effects 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 150000001347 alkyl bromides Chemical class 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 2
- 229950009221 chidamide Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006197 histone deacetylation Effects 0.000 description 2
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000004572 zinc-binding Effects 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- MOQCFMZWVKQBAP-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)benzoyl]-n-(4-chlorophenyl)piperidine-3-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(CCC2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 MOQCFMZWVKQBAP-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- AKBHYCHPWZPGAH-UHFFFAOYSA-N 2-[3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl]-7-oxa-5-azaspiro[3.4]octan-6-one Chemical compound CC1=C(Cl)C=C(COC2CN(C2)C(=O)C2CC3(C2)COC(=O)N3)C=C1 AKBHYCHPWZPGAH-UHFFFAOYSA-N 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- UQCFMEFQBSYDHY-UHFFFAOYSA-N 6-bromo-4h-1,4-benzoxazin-3-one Chemical compound O1CC(=O)NC2=CC(Br)=CC=C21 UQCFMEFQBSYDHY-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000000315 ampulla of Vater cancer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 208000017211 gastric neuroendocrine tumor G1 Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000021644 malignant soft tissue neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 1
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000017901 rectal neuroendocrine tumor G1 Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
본 발명은 신규한 2H-벤조[b][1,4]옥사진-3(4H)-온 고리를 포함하는 N-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따른 화합물은 히스톤 탈아세틸화 효소(histone deacetylase, HDAC)의 억제 활성을 가지며, 다양한 암세포에서 세포독성을 나타내어 항암 효능을 발휘하므로, 강력한 항암제로 활용할 수 있다.The present invention relates to a novel N-hydroxypropenamide compound containing a 2H-benzo[b][1,4]oxazin-3(4H)-one ring and a pharmaceutical for preventing or treating cancer containing the same as an active ingredient. It relates to composition. The compound according to the present invention has the inhibitory activity of histone deacetylase (HDAC) and exhibits anticancer efficacy by exhibiting cytotoxicity in various cancer cells, so it can be used as a powerful anticancer agent.
Description
본 발명은 신규한 N-히드록시프로펜아미드 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물에 관한 것이다.The present invention relates to a novel N-hydroxypropenamide compound and a pharmaceutical composition for preventing or treating cancer containing the same as an active ingredient.
분자 표적 기반의 약물은 오늘날 항암제 연구 및 개발의 주류를 이루고 있다. 암 병리학의 발전으로 단백질 카이네이즈(protein kinases), 파르네실 전달효소(farnesyl transferases), 텔로머레이즈(telomerases), 히스톤 탈아세틸화효소(histone deacetylases) 등과 같은 분자들이 항암제 설계의 매력적인 표적으로서 확인되고 검증되었다.Molecular target-based drugs are the mainstream of anticancer drug research and development today. With advances in cancer pathology, molecules such as protein kinases, farnesyl transferases, telomerases, histone deacetylases, etc. have been identified and validated as attractive targets for anticancer drug design. It has been done.
히스톤 탈아세틸화효소(HDAC)는 히스톤 단백질의 아세틸기 제거를 촉매하는 효소이다. 히스톤 아세틸전달효소(histone acetyl transferase, HAT)와 함께 HDAC는 후성 유전적 균형을 조절하는 데 중요한 역할을 한다. HDAC의 억제는 세포 주기 정지, 세포자멸사, 또한 세포 운동성의 감소 및 혈관신생의 억제를 유도한다. 따라서 HDAC 억제제는 다중 표적 항암제로 널리 알려져 있다. 전 세계 과학자들의 집중적인 연구로 인하여 단쇄 지방산(예: 페닐부티르산, 발프로산), 고리형 펩티드(예: 뎁시펩티드), 벤즈아미드(예: 엔티노스타트, 기비노스타트), 하이드록삼산(예: SAHA)과 같은 다양한 구조를 가진 수백 가지 HDAC 억제제가 발견되었으며, 강력한 항암 활성을 갖는 것으로 발견되고 입증되었다. 이 중 수베로일아닐리드 하이드록삼산(SAHA, Zoinza®), 벨리노스타트(PXD101), 로미뎁신(Istodax®), 파노비노스타트(LBH-589, Farydak®)(도 1)를 포함한 4가지 이상의 화합물이 다양한 유형의 암을 치료하는 용도로 미국 FDA 승인을 받았다. 또한 chidamide(Epidaza®)는 2015년 재발성 또는 불응성 말초 T 세포 림프종(peripheral T cell lymphoma)의 치료제로 중국 FDA의 승인을 받았다.Histone deacetylase (HDAC) is an enzyme that catalyzes the removal of acetyl groups from histone proteins. Together with histone acetyl transferase (HAT), HDACs play an important role in regulating epigenetic balance. Inhibition of HDAC induces cell cycle arrest, apoptosis, as well as reduction of cell motility and inhibition of angiogenesis. Therefore, HDAC inhibitors are widely known as multi-target anticancer agents. Intensive research by scientists around the world has led to the discovery of short-chain fatty acids (e.g. phenylbutyric acid, valproic acid), cyclic peptides (e.g. depsipeptide), benzamides (e.g. entinostat, gibinostat), and hydroxamic acids (e.g. Hundreds of HDAC inhibitors with different structures (e.g. SAHA) have been discovered and proven to have potent anticancer activity. Of these, four or more, including suberoylanilide hydroxamic acid (SAHA, Zoinza®), belinostat (PXD101), romidepsin (Istodax®), and panobinostat (LBH-589, Farydak®) (Figure 1). The compound has been approved by the U.S. FDA for use in treating various types of cancer. Additionally, chidamide (Epidaza®) was approved by the Chinese FDA for the treatment of relapsed or refractory peripheral T cell lymphoma in 2015.
HDAC 억제제의 구조는 아연 결합 그룹(ZBG)(일반적으로 하이드록삼산 모이어티), 링커 및 효소 활성 결합 포켓의 입구에 있는 캡 그룹을 포함하여 세 가지 독특한 부분(도 2)을 가지고 있다. 새로운 HDAC 억제제를 연구하는 과정에서 우리는 이전에 캡 그룹으로 작용하는 5-아릴-3,4,5-티아디아졸, 벤조티아졸, 2-옥소인돌린 및 4-옥소퀴나졸린과 같은 다양한 헤테로사이클의 형태를 포함하는 여러가지 히드록삼산들을 발견했다. 이러한 화합물들 중에서 특히 LBH-589(파노비노스타트) 또는 PXD-101(벨리노스타트)의 유사체로 설계된 N-하이드록시프로펜아마이드 화합물은 매우 강력한 항암 활성을 나타내었다. 이러한 결과에 영감을 받아 2H-벤조[b][1,4]옥사진-3(4H)-온(2H-benzo[b][1,4]oxazin-3(4H)-one) 고리를 포함하는 다양한 N-히드록시프로펜아미드 화합물의 설계를 확장하였다. 그리고 2H-벤조[b][1,4]옥사진-3(4H)-온 함유 화합물들의 다양한 생물학적 활성, 특히 항암 활성을 갖는 것을 발견하여 본 발명을 완성하였다.The structure of HDAC inhibitors has three distinct parts (Figure 2), including a zinc binding group (ZBG) (usually a hydroxamic acid moiety), a linker, and a cap group at the entrance to the enzymatic active binding pocket. In the process of researching new HDAC inhibitors, we have previously used various heterozygous compounds such as 5-aryl-3,4,5-thiadiazole, benzothiazole, 2-oxoindoline and 4-oxoquinazoline, which act as cap groups. Several hydroxamic acids containing cyclic forms were discovered. Among these compounds, N-hydroxypropenamide compounds, especially designed as analogs of LBH-589 (panobinostat) or PXD-101 (belinostat), showed very strong anticancer activity. Inspired by these results, 2H-benzo[b][1,4]oxazin-3(4H)-one containing the 2H-benzo[b][1,4]oxazin-3(4H)-one ring The design of various N-hydroxypropenamide compounds was expanded. The present invention was completed by discovering that 2H-benzo[b][1,4]oxazin-3(4H)-one-containing compounds have various biological activities, especially anticancer activity.
본 발명자들은 히스톤 탈아세틸화 효소(histone deacetylase, HDAC)에 대한 강력한 억제효과를 갖는 신규의 N-히드록시프로펜아미드 화합물을 개발하기 위해 연구 노력하였다. 그 결과, 2H-벤조[b][1,4]옥사진-3(4H)-온 고리를 가지는 새로운 N-히드록시프로펜아미드 화합물을 합성하는데 성공하였고, 합성한 N-히드록시프로펜아미드 화합물들이 히스톤 탈아세틸화 효소의 활성을 억제할 뿐만 아니라 다양한 종류의 암세포주에 대해 항암 활성을 가진다는 사실을 확인함으로써 본 발명을 완성하였다.The present inventors made research efforts to develop a novel N-hydroxypropenamide compound that has a strong inhibitory effect on histone deacetylase (HDAC). As a result, we succeeded in synthesizing a new N-hydroxypropenamide compound with a 2H-benzo[b][1,4]oxazin-3(4H)-one ring, and the synthesized N-hydroxypropenamide The present invention was completed by confirming that the compounds not only inhibit the activity of histone deacetylase but also have anticancer activity against various types of cancer cell lines.
본 발명의 목적은 신규한 N-히드록시프로펜아미드 화합물을 제공하는 것이다.The object of the present invention is to provide novel N-hydroxypropenamide compounds.
본 발명의 다른 목적은 신규한 N-히드록시프로펜아미드 화합물을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer containing a novel N-hydroxypropenamide compound as an active ingredient.
본 발명의 일 예는 하기 화학식 1 또는 화학식 2로 표시되는 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체를 제공한다.One example of the present invention provides a compound represented by Formula 1 or Formula 2 below and a pharmaceutically acceptable salt, hydrate, solvate, or optical isomer thereof.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
상기 화학식 1에서, R은 수소, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C1~C10 알케닐, 치환 또는 비치환된 C1~C10 알키닐, 치환 또는 비치환된 치환 또는 비치환된 C1~C30 시클로알킬 중 하나이고;In Formula 1, R is hydrogen, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 1 -C 10 alkenyl, substituted or unsubstituted C 1 -C 10 alkynyl, substituted or unsubstituted It is one of substituted or unsubstituted C 1 to C 30 cycloalkyl;
상기 화학식 2에서, R은 치환 또는 비치환된 C5~C30 아릴, 치환 또는 비치환된 아릴알킬, 치환 또는 비치환된 아릴알케닐, 치환 또는 비치환된 아릴알키닐 중 하나이며;In Formula 2, R is one of substituted or unsubstituted C 5 to C 30 aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted arylalkenyl, or substituted or unsubstituted arylalkynyl;
상기 치환은 하나 이상의 수소를 불소, 염소, 브롬 및 요오드와 같은 할로겐; 히드록시; 니트로; 시아노; 옥소(=O); 티옥소(=S); 아지도; 니트로소; 아미노; 히드라지노; 포르밀; 알킬; 알콕시; 아릴; 트리플루오로메틸, 트리브로모메틸, 트리클로로메틸 등과 같은 할로알킬 그룹으로 바꾼 것이다.The substitution involves replacing one or more hydrogens with halogens such as fluorine, chlorine, bromine and iodine; hydroxy; nitro; cyano; oxo (=O); Thioxo (=S); Azido; nitroso; Amino; hydrazino; formyl; alkyl; alkoxy; aryl; It is changed to haloalkyl groups such as trifluoromethyl, tribromomethyl, and trichloromethyl.
본 발명의 다른 일 예는 상기 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물을 제공한다.Another example of the present invention provides a pharmaceutical composition for preventing or treating cancer containing the above compound and its pharmaceutically acceptable salt, hydrate, solvate, or optical isomer as an active ingredient.
본 발명에 따른 신규한 N-히드록시프로펜아미드 화합물은 히스톤 탈아세틸화 효소(histone deacetylase, HDAC)의 억제 활성을 가지며, 다양한 암세포에서 세포독성을 나타내어 항암 효능을 발휘하므로, 강력한 항암제의 활성성분으로 개발될 수 있다.The novel N-hydroxypropenamide compound according to the present invention has inhibitory activity on histone deacetylase (HDAC) and exhibits anticancer efficacy by exhibiting cytotoxicity in various cancer cells, so it is an active ingredient of a powerful anticancer agent. can be developed.
도 1은 다양한 히스톤 탈아세틸화 효소들의 화학구조를 나타낸 도이다.
도 2는 히스톤 탈아세틸화 효소(벨리노스타트)의 CAP 부분, 링커 부분, 아연 결합 그룹(ZBG) 부분을 표시하여 나타낸 도이다.
도 3은 2H-벤조[b][1,4]옥사진-3(4H)-온고리를 포함하는 다양한 N-히드록시프로펜아미드 화합물의 합성 메커니즘을 나타낸 도이다.
도 4는 화합물 7f를 암세포(SW620)에 처리한 경우의 DNA 함량, 세포주기를 분석한 그래프이다.
도 5는 화합물 7f를 암세포(SW620)에 처리한 경우의 세포자멸을 수행중인 세포를 분석한 그래프이다.
도 6은 화합물 7f를 암세포(SW620)에 처리한 경우의 세포 형태를 A)는 20배, B)는 40배 확대 촬영하여 나타낸 도이다.Figure 1 is a diagram showing the chemical structures of various histone deacetylation enzymes.
Figure 2 is a diagram showing the CAP portion, linker portion, and zinc binding group (ZBG) portion of histone deacetylase (belinostat).
Figure 3 is a diagram showing the synthesis mechanism of various N-hydroxypropenamide compounds containing a 2H-benzo[b][1,4]oxazine-3(4H)-one ring.
Figure 4 is a graph analyzing DNA content and cell cycle when cancer cells (SW620) were treated with compound 7f.
Figure 5 is a graph analyzing cells undergoing apoptosis when cancer cells (SW620) were treated with compound 7f.
Figure 6 is a diagram showing the cell morphology when cancer cells (SW620) were treated with compound 7f at 20 times magnification in A) and 40 times magnification in B).
본 명세서 전체에서 특별한 언급이 없는 한 "포함" 또는 "함유"라 함은 어떤 구성 요소(또는 구성 성분)를 별다른 제한 없이 포함함을 지칭하며, 다른 구성 요소(또는 구성 성분)의 부가를 제외하는 것으로 해석될 수 없다.Throughout this specification, unless otherwise specified, “include” or “contains” refers to the inclusion of a certain component (or component) without particular limitation, excluding the addition of other components (or components). cannot be interpreted as
본 명세서에서 사용된 용어 “치료(treatment)”란 질병을 앓거나 또는 질병이 발병할 위험이 있는 개체에게, 상기 개체의 상태의 개선, 질병 진행의 지연, 증상 발생의 지연 또는 증상 진행의 둔화 등을 포함한 효과를 제공하는 임의의 형태의 치료 또는 예방(prevention)을 의미한다. 따라서, 용어 “치료”는 증상의 발생을 예방하는, 개체의 예방적 치료를 포함한다. 또한, 상기 “치료” 및 “예방”은 증상의 치유 또는 완전한 제거를 의미하도록 의도되지 않는다.As used herein, the term “treatment” means, for an individual suffering from a disease or at risk of developing a disease, improving the condition of the individual, delaying the progression of the disease, delaying the onset of symptoms, or slowing the progression of symptoms, etc. It means any form of treatment or prevention that provides effects including. Accordingly, the term “treatment” includes prophylactic treatment of an individual, preventing the occurrence of symptoms. Additionally, the terms “treatment” and “prevention” are not intended to imply cure or complete elimination of symptoms.
본 명세서에서 사용된 용어 “약학적으로 허용 가능한”은 대상체, 예컨대 인간 대상체에 투여될 때 생리학적으로 용인 가능하고, 전형적으로 알레르기 반응 또는 유사한 부작용을 생산하지 않는 조성물을 말한다. 예를 들어, 인간에서의 사용에 대하여 주 정부 또는 연방 정부의 규제 기관에 의해 승인되었거나, 대한민국 약전(Korean Pharmacopoeia), 미국 약전 또는 다른 일반적으로 인정되는 약전에 나열되었음을 의미할 수 있다.As used herein, the term “pharmaceutically acceptable” refers to a composition that is physiologically acceptable when administered to a subject, such as a human subject, and typically does not produce an allergic reaction or similar adverse effect. For example, this may mean approved by a state or federal regulatory agency for use in humans, or listed in the Korean Pharmacopoeia, United States Pharmacopoeia, or other generally accepted pharmacopoeia.
본 명세서에서 사용된 용어 "암", "신생물", 및 "종양"은 세포 증식에 대한 제어의 상당한 상실을 특징으로 하는 비정상적인 성장 표현형을 나타내도록 자율적이고 비조절된 성장을 나타내는 세포를 지칭하기 위해 본원에서 사용된다. 본 발명의 맥락에서 검출, 분석 및/또는 치료를 위한 관심 세포는 암 세포(예를 들어, 암에 걸린 개체로부터의 암 세포), 악성 암 세포, 전-전이성 암 세포, 전이성 암 세포, 및 비-전이성 암 세포를 포함한다. 거의 모든 조직의 암이 알려져 있다.As used herein, the terms “cancer,” “neoplasm,” and “tumor” refer to cells that exhibit autonomous, uncontrolled growth, resulting in an abnormal growth phenotype characterized by significant loss of control over cell proliferation. It is used in this institution for this purpose. Cells of interest for detection, analysis, and/or treatment in the context of the present invention include cancer cells (e.g., cancer cells from an individual with cancer), malignant cancer cells, pre-metastatic cancer cells, metastatic cancer cells, and non-metastatic cancer cells. -Contains metastatic cancer cells. Cancer of almost all tissues is known.
본 명세서에서 사용된 용어 "암 세포"는 암 세포(예를 들어, 개체가 치료될 수 있는 임의의 암, 예를 들어, 암에 걸린 개체로부터 단리될 수 있는 것)이거나 암세포로부터 유래된, 예를 들어, 암 세포의 클론인 임의의 세포를 지칭한다. 예를 들어, 암세포는 확립된 암 세포주로부터 유래할 수 있고, 암에 걸린 개체로부터 단리된 1차 세포일 수 있고, 암에 걸린 개체로부터 단리된 1차 세포로부터의 자손 세포 등일 수 있다. 일부 구체예에서, 상기 용어는 또한 암 세포의 일부, 예를 들어 세포내 부분, 세포막 부분, 또는 암세포의 세포 용해물을 지칭할 수 있다. 암종, 육종, 교모세포종, 흑색종, 림프종 및 골수종과 같은 고형 종양, 및 백혈병과 같은 순환성 암을 비롯한 많은 유형의 암이 통상의 기술자에게 공지되어 있다.As used herein, the term “cancer cell” refers to a cancer cell (e.g., one that can be isolated from an individual with cancer, e.g., any cancer for which the individual can be treated) or derived from a cancer cell, e.g. For example, it refers to any cell that is a clone of a cancer cell. For example, the cancer cells can be derived from an established cancer cell line, can be a primary cell isolated from an individual with cancer, can be progeny cells from a primary cell isolated from an individual with cancer, etc. In some embodiments, the term may also refer to a portion of a cancer cell, such as an intracellular portion, a cell membrane portion, or a cell lysate of a cancer cell. Many types of cancer are known to those skilled in the art, including solid tumors such as carcinomas, sarcomas, glioblastomas, melanomas, lymphomas, and myeloma, and circulatory cancers such as leukemias.
본 발명의 일 구현예는 하기 화학식 1 또는 화학식 2로 표시되는 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체를 제공한다.One embodiment of the present invention provides a compound represented by Formula 1 or Formula 2 below and a pharmaceutically acceptable salt, hydrate, solvate, or optical isomer thereof.
[화학식 1][Formula 1]
[화학식 2][Formula 2]
상기 화학식 1에서, R은 수소, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C1~C10 알케닐, 치환 또는 비치환된 C1~C10 알키닐, 치환 또는 비치환된 치환 또는 비치환된 C1~C30 시클로알킬 중 하나이고;In Formula 1, R is hydrogen, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 1 -C 10 alkenyl, substituted or unsubstituted C 1 -C 10 alkynyl, substituted or unsubstituted It is one of substituted or unsubstituted C 1 to C 30 cycloalkyl;
상기 화학식 2에서, R은 치환 또는 비치환된 C5~C30 아릴, 치환 또는 비치환된 아릴알킬, 치환 또는 비치환된 아릴알케닐, 치환 또는 비치환된 아릴알키닐 중 하나이며;In Formula 2, R is one of substituted or unsubstituted C 5 to C 30 aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted arylalkenyl, or substituted or unsubstituted arylalkynyl;
상기 치환은 하나 이상의 수소를 불소, 염소, 브롬 및 요오드와 같은 할로겐; 히드록시; 니트로; 시아노; 옥소(=O); 티옥소(=S); 아지도; 니트로소; 아미노; 히드라지노; 포르밀; 알킬; 알콕시; 아릴; 트리플루오로메틸, 트리브로모메틸, 트리클로로메틸 등과 같은 할로알킬 그룹, 바람직하게는 불소, 염소, 브롬, 히드록시, 알킬일 수 있다.The substitution involves replacing one or more hydrogens with halogens such as fluorine, chlorine, bromine and iodine; hydroxy; nitro; cyano; oxo (=O); Thioxo (=S); Azido; nitroso; Amino; hydrazino; formyl; alkyl; alkoxy; aryl; It may be a haloalkyl group such as trifluoromethyl, tribromomethyl, trichloromethyl, etc., preferably fluorine, chlorine, bromine, hydroxy, or alkyl.
상기 화합물에서, 할로겐이 존재하는 경우, 상기 할로겐은 불소, 염소, 브롬 또는 요오드이며; 알킬 그룹이 존재하는 경우, 상기 알킬 그룹은 메틸, 에틸, n-프로필, 이소프로필, 부틸, 이소부틸, t-부틸, 펜틸, 헥실, 헵틸, 옥틸 또는 이의 치환된 것이며;In the above compounds, when halogen is present, the halogen is fluorine, chlorine, bromine or iodine; If an alkyl group is present, the alkyl group is methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl or substituted thereof;
시클로알킬 그룹이 존재하는 경우, 상기 시클로알킬 그룹은 시클로프로필, 시클로부틸, 시클로펜틸, 시클로헥실, 시클로옥틸, 시클로헵틸, 퍼히드로나프틸, 아다만틸, 가교된 시클릭 그룹들 또는 스피로비시클릭 그룹들(spirobicyclic groups)이며;When present, the cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, perhydronaphthyl, adamantyl, bridged cyclic groups or spirobicyclic groups. are spirobicyclic groups;
아릴 그룹이 존재하는 경우, 상기 아릴 그룹은 페닐, 나프틸, 안트라세닐, 인다닐 또는 비페닐이며;If an aryl group is present, the aryl group is phenyl, naphthyl, anthracenyl, indanyl or biphenyl;
히드록시알킬 그룹이 존재하는 경우, 상기 히드록시알킬 그룹은 히드록시메틸 또는 히드록시에틸일 수 있다.If a hydroxyalkyl group is present, the hydroxyalkyl group may be hydroxymethyl or hydroxyethyl.
구체적으로, 상기 화학식 1에서 R은 에틸, 2-클로로에틸, 2-히드록시에틸, n-프로필, n-부틸, , , 또는 일 수 있고, 상기 화학식 2에서 R은 , , , , , 또는 일 수 있다. Specifically, in Formula 1, R is ethyl, 2-chloroethyl, 2-hydroxyethyl, n-propyl, n-butyl, , , or It may be, and in Formula 2, R is , , , , , or It can be.
예를 들면, 상기 화학식 1 또는 화학식 2로 표시되는 화합물은 다음의 화합물 중 어느 하나일 수 있다:For example, the compound represented by Formula 1 or Formula 2 may be any of the following compounds:
(E)-3-(4-에틸-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide;
(E)-3-(4-(클로로에틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(chloroethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide ;
(E)-N-히드록시-3-(4-(히드록시메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)아크릴아미드;(E)-N-hydroxy-3-(4-(hydroxymethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylic amides;
(E)-N-히드록시-3-(3-옥소-4-프로필-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)아크릴아미드;(E)-N-hydroxy-3-(3-oxo-4-propyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamide;
(E)-3-(4-부틸-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide;
(E)-3-(4-(시클로프로필메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(cyclopropylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-(시클로부틸메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(Cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-(시클로펜틸메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(cyclopentylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-(시클로헥실메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(cyclohexylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-벤질-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-benzyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide;
(E)-3-(4-(2-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide;
(E)-3-(4-(3-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(3-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide;
(E)-3-(4-(4-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide;
(E)-3-(4-(4-클로로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;(E)-3-(4-(4-chlorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxy acrylamide;
(E)-3-(4-(4-브로모벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드; 및(E)-3-(4-(4-bromobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide; and
(E)-N-히드록시-3-(4-(4-메틸벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)아크릴아미드일 수 있다.(E)-N-hydroxy-3-(4-(4-methylbenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl) It may be acrylamide.
본 발명의 다른 구현예는 상기 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물을 제공한다.Another embodiment of the present invention provides a pharmaceutical composition for preventing or treating cancer containing the above compound and its pharmaceutically acceptable salt, hydrate, solvate, or optical isomer as an active ingredient.
상기 약학적 조성물은 펩티드 화합물, 이의 입체이성질체, 광학이성질체, 수화물, 용매화물, 또는 약학적으로 허용가능한 염을 유효 성분으로 포함할 수 있다. 상기 약학적 조성물은 항암 활성을 갖는 공지의 유효 성분을 더 포함할 수 있다. 상기 약학적 조성물은 약제학적으로 허용가능한 희석제 또는 담체를 추가적으로 포함할 수 있다. 상기 희석제는 유당, 옥수수 전분, 대두유, 미정질 셀룰로오스, 또는 만니톨, 활택제로는 스테아린산 마그네슘, 탈크, 또는 그 조합일 수 있다. 상기 담체는 부형제, 붕해제, 결합제, 활택제, 또는 그 조합일 수 있다. 상기 부형제는 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오즈, 또는 그 조합일 수 있다. 상기 붕해제는 카르복시메틸셀룰로오스 칼슘, 전분글리콜산 나트륨, 무수인산일수소 칼슘, 또는 그 조합일 수 있다. 상기 결합제는 폴리비닐피롤리돈, 저치환도 히드록시프로필셀룰로오즈, 히드록시프로필셀룰로오즈, 또는 그 조합일 수 있다. 상기 활택제는 스테아린산 마그네슘, 이산화규소, 탈크, 또는 그 조합일 수 있다.The pharmaceutical composition may include a peptide compound, a stereoisomer, an optical isomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition may further include known active ingredients with anticancer activity. The pharmaceutical composition may additionally include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, disintegrant, binder, lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium monohydrogen phosphate anhydride, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
상기 약학적 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화될 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions according to conventional methods. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
상기 약학적 조성물에 있어서, 경구 투여를 위한 고형 제제는 정제, 환제, 산제, 과립제, 또는 캡슐제일 수 있다. 상기 고형 제제는 부형제를 더 포함할 수 있다. 부형제는 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose), 락토오스(lactose), 또는 젤라틴일 수 있다. 또한, 상기 고형 제제는 마그네슘 스테아레이트, 또는 탈크와 같은 윤활제를 더 포함할 수 있다. 상기 약학적 조성물에 있어서, 경구를 위한 액상제제는 현탁제, 내용액제, 유제, 또는 시럽제일 수 있다. 상기 액상 제제는 물, 또는 리퀴드 파라핀을 포함할 수 있다. 상기 액상 제제는 부형제, 예를 들면 습윤제, 감미제, 방향제, 또는 보존제를 포함할 수 있다. 상기 약학적 조성물에 있어서, 비경구 투여를 위한 제제는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 또는 및 좌제일 수 있다. 비수성용제 또는 현탁제는 식물성 기름 또는 에스테르를 포함할 수 있다. 식물성 기름은 예를 들면, 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 또는 올리브 오일일 수 있다. 에스테르는 예를 들면 에틸올레이트일 수 있다. 좌제의 기제는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 또는 글리세로젤라틴일 수 있다. 상기 약학적 조성물의 바람직한 투여량은 개체의 상태 및 체중, 질병의 정도, 약물 형태, 투여 경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 상기 화합물, 이의 이성질체, 유도체, 용매화물, 또는 약학적으로 허용가능한 염은 예를 들면, 약 0.0001 ㎎/㎏ 내지 약 100 ㎎/㎏, 또는 약 0.001 ㎎/㎏ 내지 약 100 ㎎/㎏의 양을 일일 1회 내지 24회, 2일 내지 1주에 1 내지 7회, 또는 1개월 내지 12개월에 1 내지 24회로 나누어 투여할 수 있다. 상기 약학적 조성물에서 화합물, 이의 이성질체, 유도체, 용매화물, 또는 약학적으로 허용가능한 염은 전체 조성물 총 중량에 대하여 약 0.0001 중량% 내지 약 10 중량%, 또는 약 0.001 중량% 내지 약 1 중량%로 포함될 수 있다.In the pharmaceutical composition, the solid preparation for oral administration may be a tablet, pill, powder, granule, or capsule. The solid preparation may further include excipients. Excipients may be, for example, starch, calcium carbonate, sucrose, lactose, or gelatin. Additionally, the solid preparation may further include a lubricant such as magnesium stearate or talc. In the pharmaceutical composition, the oral liquid preparation may be a suspension, oral solution, emulsion, or syrup. The liquid formulation may contain water or liquid paraffin. The liquid formulation may contain excipients such as wetting agents, sweeteners, flavoring agents, or preservatives. In the pharmaceutical composition, preparations for parenteral administration may be sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried products, and suppositories. Non-aqueous solvents or suspensions may contain vegetable oil or ester. The vegetable oil may be, for example, propylene glycol, polyethylene glycol, or olive oil. The ester may be, for example, ethyl oleate. The base of the suppository may be witepsol, macrogol, tween 61, cacao, laurel, or glycerogelatin. The preferred dosage of the pharmaceutical composition varies depending on the individual's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art. However, the compound, its isomer, derivative, solvate, or pharmaceutically acceptable salt may be used in an amount of, for example, about 0.0001 mg/kg to about 100 mg/kg, or about 0.001 mg/kg to about 100 mg/kg. The amount can be divided and administered 1 to 24 times per day, 1 to 7 times per 2 days to 1 week, or 1 to 24 times per month to 12 months. In the pharmaceutical composition, the compound, its isomer, derivative, solvate, or pharmaceutically acceptable salt is present in an amount of about 0.0001% to about 10% by weight, or about 0.001% to about 1% by weight, based on the total weight of the composition. may be included.
상기 “암”은 조직 내에서 무제한의 증식을 하는, 미분화된 세포로 구성된 종괴(腫塊) 또는 종양을 말한다. 상기 약학적 조성물은 어떠한 암에도 사용될 수 있으며, 췌장암, 결장암, 폐암, 유방암, 위암, 간암, 대장암, 피부암, 두부 또는 경부암, 자궁암, 난소암, 뇌암, 후두암, 전립선암, 방광암, 식도암, 갑상선암, 방광암, 신장암, 또는 직장암일 수 있다.The term “cancer” refers to a mass or tumor composed of undifferentiated cells that proliferates without limit within the tissue. The pharmaceutical composition can be used for any cancer, including pancreatic cancer, colon cancer, lung cancer, breast cancer, stomach cancer, liver cancer, colon cancer, skin cancer, head or neck cancer, uterine cancer, ovarian cancer, brain cancer, laryngeal cancer, prostate cancer, bladder cancer, esophagus cancer, and thyroid cancer. , it may be bladder, kidney, or rectal cancer.
상기 암은 예를 들면 간내 담관암, 간암, 갑상선암, 결장암, 고환암, 골수이형성증후군, 교모세포종, 구강암, 균상식육종, 급성 골수성 백혈병, 만성 골수성 백혈병, 급성 림프구성 백혈병, 만성 림프구 백혈병, 기저세포암, 난소 상피암, 난소 생식 세포 종양, 남성 유방암, 뇌종양, 뇌하수체선종, 다발성 골수종, 담낭암, 담도암, 대장암, 망막모세포종, 맥락막흑색종, 바터팽대부암, 방광암, 복막암, 부갑상선암, 부신암, 비소세포폐암, 설암, 성상세포종, 소세포폐암, 소아 뇌종양, 소아 림프종, 소아 백혈병, 소장암, 수막종, 식도암, 신경교종, 신경모세포종, 신우요관암, 신장암, 악성 연부 조직 종양, 악성 골종양, 악성 림프종, 악성 중피종, 악성흑색종, 안종양, 외음부암, 요도암, 원발부위 불명암, 위림프종, 위암, 위유암종, 위장관 간질 종양, 윌름종양, 유방암, 육종, 음경암, 인두암, 임신 융모 질환, 자궁경부암, 자궁내막암, 자궁육종, 전립선암, 전이성 뇌종양, 직장암, 직장유암종, 질암, 척수종양, 청신경초종, 췌장암, 침샘암, 편도암, 편평상피세포암, 폐선암, 폐암, 폐편평상피세포암, 피부암, 항문암, 후두암 또는 이들의 조합일 수 있으며, 상기 암은 예를 들어 유방암, 폐암, 위암, 간암, 혈액암, 뼈암, 췌장암, 결장암, 피부암, 두경부암, 피부 또는 안구 흑색종, 자궁육종, 난소암, 직장암, 항문암, 대장암, 난관암, 자궁내막암, 자궁경부암, 소장암, 내분비암, 갑상선암, 부갑상선암, 신장암, 연조직종양, 요도암, 전립선암, 기관지암, 또는 골수암일 수 있다.The above cancers include, for example, intrahepatic bile duct cancer, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, mycosis fungoides, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and basal cell cancer. , ovarian epithelial cancer, ovarian germ cell tumor, male breast cancer, brain tumor, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colon cancer, retinoblastoma, choroidal melanoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, Non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain tumor, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, neuroblastoma, pyeloureteral cancer, kidney cancer, malignant soft tissue tumor, malignant bone tumor, malignant Lymphoma, malignant mesothelioma, malignant melanoma, eye tumor, vulvar cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, stomach cancer, gastric carcinoid tumor, gastrointestinal stromal tumor, Wilm's tumor, breast cancer, sarcoma, penile cancer, pharyngeal cancer, gestational villi. Diseases, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic brain tumor, rectal cancer, rectal carcinoid, vaginal cancer, spinal tumor, acoustic neurula, pancreatic cancer, salivary gland cancer, tonsil cancer, squamous cell carcinoma, pulmonary adenocarcinoma, lung cancer, lung It may be squamous cell cancer, skin cancer, anal cancer, laryngeal cancer, or a combination thereof, which cancers include, for example, breast cancer, lung cancer, stomach cancer, liver cancer, blood cancer, bone cancer, pancreas cancer, colon cancer, skin cancer, head and neck cancer, skin or eye cancer. Melanoma, uterine sarcoma, ovarian cancer, rectal cancer, anal cancer, colon cancer, fallopian tube cancer, endometrial cancer, cervical cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, kidney cancer, soft tissue tumor, urethral cancer, prostate cancer, It may be bronchial cancer, or bone marrow cancer.
상기 화합물은 히스톤 탈아세틸화효소(histone deacetylase)의 억제를 통해 히스톤의 아세틸화를 촉진하는 활성을 갖는 것을 특징으로 하는 암의 예방 또는 치료용 약제학적 조성물일 수 있다. 구체적으로, 본 발명의 화합물은 히스톤 탈아세틸화 효소의 활성을 억제함으로써 세포내 히스톤을 고아세틸화 상태로 유도할 수 있다.The compound may be a pharmaceutical composition for the prevention or treatment of cancer, characterized in that it has the activity of promoting histone acetylation through inhibition of histone deacetylase. Specifically, the compounds of the present invention can induce intracellular histones into a hyperacetylated state by inhibiting the activity of histone deacetylation enzymes.
이하 본 발명을 실험예 및 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실험예 및 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실험예 및 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through experimental examples and examples. However, these experimental examples and examples are for illustrative purposes only and the scope of the present invention is not limited to these experimental examples and examples.
또한, 본 명세서에서 특별한 정의가 없으면, 본 명세서에 사용된 모든 과학적 및 기술적인 용어는 본 발명이 속하는 기술 분야에서 당업자에 의하여 통상적으로 이해되는 것과 동일한 의미를 가질 수 있다.In addition, unless there is a special definition in this specification, all scientific and technical terms used in this specification may have the same meaning as commonly understood by a person skilled in the art in the technical field to which the present invention pertains.
화학물질chemical substance
Whatman® 250 Jm mSilica Gel GF Uniplates를 사용하여 박막 크로마토그래피(thin layer chromatography)를 수행하였고 254 및 365 nm 파장의 UV 광선에서 시각화하여 반응의 진행 상황을 확인하고 화합물의 균질성에 대한 예비 평가를 수행하였다. 녹는점은 Gallenkamp Melting Point Apparatus(LabMerchant, London, United Kingdom)를 사용하여 측정하였으며 별도 보정하지 않았다. 화합물의 정제는 고정상으로서 Merck 실리카겔 60(240 내지 400 메쉬)을 사용하는 결정화 방법 및/또는 개방형 실리카겔 컬럼 플래시 크로마토그래피를 사용하였다. 핵 자기 공명 스펙트럼(1H NMR)은 달리 표시되지 않는 한 용매로서 DMSO-d 6 을 사용하여 Bruker 500 MHz 분광계에서 측정하였다. 테트라메틸실란(tetramethylsilane)을 내부 표준으로 사용하였으며, 화학적 이동은 테트라메틸실란으로부터 다운필드로 백만분율(ppm) 단위로 측정하였다. 전자 이온화(EI), Electrospray 이온화(ESI)를 포함한 다양한 이온화 모드를 갖는 질량 스펙트럼은 각각 PE Biosystems API2000(Perkin Elmer, Palo Alto, CA, USA) 및 Mariner®(Azco Biotech, Inc. Oceanside, CA, USA) 질량 분석기를 통해 측정하였다. 원소(C, H, N) 분석은 Perkin Elmer 모델 2400 원소 분석기에서 수행하였다. 모든 시약 및 용매는 달리 명시되지 않는 한 Aldrich 또는 Fluka Chemical Corp.(Milwaukee, WI, USA) 또는 Merck사에서 구입하였다. 용매는 달리 표시되지 않는 한 구입한 그대로 사용하였다.Thin layer chromatography was performed using Whatman® 250 J mSilica Gel GF Uniplates and visualized under UV light at 254 and 365 nm wavelengths to confirm the progress of the reaction and perform a preliminary assessment of the homogeneity of the compounds. . The melting point was measured using the Gallenkamp Melting Point Apparatus (LabMerchant, London, United Kingdom) and was not separately corrected. Purification of the compound was performed using a crystallization method using Merck silica gel 60 (240 to 400 mesh) as a stationary phase and/or open silica gel column flash chromatography. Nuclear magnetic resonance spectra ( 1H NMR) were measured on a Bruker 500 MHz spectrometer using DMSO- d6 as the solvent unless otherwise indicated. Tetramethylsilane was used as an internal standard, and the chemical shift was measured in parts per million (ppm) downfield from tetramethylsilane. Mass spectra with various ionization modes, including electron ionization (EI) and electrospray ionization (ESI), were collected using PE Biosystems API2000 (Perkin Elmer, Palo Alto, CA, USA) and Mariner® (Azco Biotech, Inc. Oceanside, CA, USA), respectively. ) was measured through mass spectrometry. Elemental (C, H, N) analysis was performed on a Perkin Elmer model 2400 elemental analyzer. All reagents and solvents were purchased from Aldrich or Fluka Chemical Corp. (Milwaukee, WI, USA) or Merck, unless otherwise specified. Solvents were used as purchased unless otherwise indicated.
<실시예><Example>
실시예 1. 알킬 치환체를 포함하는 N-히드록시프로펜아미드 화합물의 제조Example 1. Preparation of N-hydroxypropenamide compounds containing alkyl substituents
DMF(10 mL)내의 6-브로모-2H-벤조[b][1,4]옥사진-3(4H)-온(화합물 1, 2 mmol) 용액에 K2CO3(342.5 mg, 2.5mmol)를 첨가하였다. 생성된 혼합물을 30분 동안 교반하면서 80℃에서 가열한 다음, KI(16.6 mg, 0.1 mmol)를 첨가하였다. 다시 15분 동안 교반한 후, DMF(1 mL)로 희석된 알킬 브로마이드(2.0 mmol 를 혼합물에 적가하였다. 혼합물을 반응이 완료될 때까지(6시간, 박막 크로마토그래피로 확인) 60℃에서 다시 교반하고, 생성된 혼합물을 얼음물(10 mL)에 부었다. 이렇게 얻어진 갈색 침전물을 물로 세척하고 24시간 동안 진공 하에 40℃에서 건조시켰다. 상기 화합물을 추가 정제 없이 다음 단계에 사용하였다.K 2 CO 3 (342.5 mg, 2.5 mmol) in a solution of 6-bromo-2H - benzo[b][1,4]oxazin-3(4H)-one (Compound 1, 2 mmol) in DMF (10 mL). ) was added. The resulting mixture was heated at 80° C. with stirring for 30 minutes, then KI (16.6 mg, 0.1 mmol) was added. After stirring for another 15 minutes, alkyl bromide (2.0 mmol) diluted with DMF (1 mL) was added dropwise to the mixture. The mixture was stirred again at 60°C until the reaction was complete (6 hours, confirmed by thin layer chromatography). The resulting mixture was poured into ice water (10 mL). The brown precipitate thus obtained was washed with water and dried under vacuum for 24 hours at 40° C. The compound was used in the next step without further purification.
다음 단계에서, 중간체(화합물 2, 1.5 mmol) 함유 DMF(10 mL) 용액에 건조된 트리에틸아민(0.5 mL) 및 에틸 아크릴레이트(0.5 mL)를 첨가하였다. 추가 15분 동안 교반한 후, 트리페닐포스핀(105 mg, 0.5 mL, 0.4 mmol) 및 팔라듐 디아세테이트(0.2 mmol, 45 mg)의 용액을 첨가하였다. 혼합물을 110 ℃에서 8시간 동안 가열하였다. 반응이 완료된 후, 혼합물을 실온으로 냉각시킨 다음, 얼음물에 부었다. 불용성 물질은 여과하였다. 고체를 수집하고 진공상태, 40 ℃에서 24시간 동안 건조시켰다. 그 다음 생성물을 컬럼 크로마토그래피(실리카겔; DCM/메탄올 = 100/5)로 정제하여 중간체 에스테르 (화합물 3a-3i)을 65-79%의 수율로 얻었다.In the next step, dried triethylamine (0.5 mL) and ethyl acrylate (0.5 mL) were added to the DMF (10 mL) solution containing the intermediate (Compound 2, 1.5 mmol). After stirring for an additional 15 minutes, a solution of triphenylphosphine (105 mg, 0.5 mL, 0.4 mmol) and palladium diacetate (0.2 mmol, 45 mg) was added. The mixture was heated at 110° C. for 8 hours. After the reaction was complete, the mixture was cooled to room temperature and then poured into ice water. Insoluble material was filtered off. The solid was collected and dried under vacuum at 40°C for 24 hours. The product was then purified by column chromatography (silica gel; DCM/methanol = 100/5) to obtain intermediate esters (compounds 3a-3i) in a yield of 65-79%.
상기 중간체 에스테르 (화합물 3a-3i) 함유 DMF(10 mL)를 각각 메탄올(10 mL)에 용해시켰다. 그 다음 히드록실아민, HCl(685 mg, 10 mmol)을 첨가하고, NaOH 수용액(1 mL, 400 mg)을 적가하였다. 그 후, 혼합물을 반응이 완료될 때까지 0 ℃에서 1-2시간 교반하였다. TLC로 확인하여 반응이 끝나면 생성된 혼합물을 얼음물에 붓고 HCl 5% 용액으로 pH 7이 될 때까지 중화하였다. 침전물을 여과하고, 건조시키고, 메탄올에서 재결정화하여 하기의 목적 화합물 (화합물 4a-4i)을 얻었다(도 3):DMF (10 mL) containing the above intermediate esters (Compounds 3a-3i) was dissolved in methanol (10 mL). Then, hydroxylamine, HCl (685 mg, 10 mmol) was added, and aqueous NaOH solution (1 mL, 400 mg) was added dropwise. Afterwards, the mixture was stirred at 0 °C for 1-2 hours until the reaction was complete. When the reaction was completed as confirmed by TLC, the resulting mixture was poured into ice water and neutralized with 5% HCl solution until pH reached 7. The precipitate was filtered, dried, and recrystallized from methanol to obtain the following desired compounds (compounds 4a-4i) (Figure 3):
화합물 4a: (E)-3-(4-에틸-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드Compound 4a: (E)-3-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide
수율: 55%. mp: 167-168 ℃. Rf = 0.40 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3202 (OH); 2922 (CH, aren); 2851 (CH, CH2); 1668 (C=O); 1603 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 7.49 (1H, d, J = 16.00 Hz, H-3); 7.42 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.06 (1H, d, J = 10.50 Hz, H-8'); 6.44 (1H, d, J = 15.50 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b); 3.99-3.98 (2H, m , H-1”a, H-1”b); 1.18 (3H, t, J = 6.50 Hz, -CH3). 13C-NMR (125 MHz, DMSO-d 6 ): δ 163.75, 163.32, 146.28, 138.27, 134.97, 134.89, 130.90, 130.32, 128.82, 122.77, 118.54, 117.54, 115.19, 67.47, 21.86, 14.41. ESI-MS m/z: 261.0866 [M-H]-.Yield: 55%. mp: 167-168℃. Rf = 0.40 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3202 (OH); 2922 (CH, aren); 2851 (CH, CH 2 ); 1668 (C=O); 1603 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 7.49 (1H, d, J = 16.00 Hz, H-3); 7.42 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.06 (1H, d, J = 10.50 Hz, H-8'); 6.44 (1H, d, J = 15.50 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b); 3.99-3.98 (2H, m, H-1”a, H-1”b); 1.18 (3H, t, J = 6.50 Hz, -CH 3 ). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 163.75, 163.32, 146.28, 138.27, 134.97, 134.89, 130.90, 130.32, 128.82, 122.77, 118.54, 117.54, 1 15.19, 67.47, 21.86, 14.41. ESI-MS m/z: 261.0866 [MH] - .
화합물 4b: (E)-3-(4-(클로로에틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드 Compound 4b: (E)-3-(4-(chloroethyl)-3-oxo-3,4-dihydro-2H- benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide
수율: 52%. mp: 172-173 ℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3204 (OH); 2955, 2920 (CH, aren); 2851 (CH, CH2); 1682 (C=O); 1597 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 7.50 (1H, d, J = 15.50 Hz, H-3); 7.40 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.40 (1H, d, J = 15.50 Hz, H-2); 4.67 (2H, s, H-2'a, H-2'b); 3.95 (2H, t, J = 6.75 Hz, H-2”a, H-2”b); 3.68 (2H, t, J = 5.25 Hz, H-1”a, H-1”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.39, 144.76, 133.62, 132.80, 132.52, 132.50, 132.00, 131.92, 131.38, 129.28, 129.18, 126.28, 119.10, 118.74, 114.42, 67.51, 58.25, 44.02. ESI-MS m/z: 297.0646 (35Cl), 299.0626 (37Cl) [M+H]+.Yield: 52%. mp: 172-173℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3204 (OH); 2955, 2920 (CH, aren); 2851 (CH, CH 2 ); 1682 (C=O); 1597 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 7.50 (1H, d, J = 15.50 Hz, H-3); 7.40 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.40 (1H, d, J = 15.50 Hz, H-2); 4.67 (2H, s, H-2'a, H-2'b); 3.95 (2H, t, J = 6.75 Hz, H-2”a, H-2”b); 3.68 (2H, t, J = 5.25 Hz, H-1”a, H-1”b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.39, 144.76, 133.62, 132.80, 132.52, 132.50, 132.00, 131.92, 131.38, 129.28, 129.18, 126.28, 1 19.10, 118.74, 114.42, 67.51, 58.25, 44.02 . ESI-MS m/z: 297.0646 ( 35 Cl), 299.0626 ( 37 Cl) [M+H] + .
화합물 4c: (E)-N-히드록시-3-(4-(히드록시메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)아크릴아미드Compound 4c: (E)-N-Hydroxy-3-(4-(hydroxymethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6- 1) Acrylamide
수율: 59%. mp: 169-170 ℃. Rf = 0.37 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3383 (NH); 3217 (OH); 2953, 2918 (CH, aren); 2851 (CH, CH2); 1668 (C=O); 1599 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 7.50 (1H, d, J = 15.50 Hz, H-3); 7.40 (1H, s, H-5’); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.40 (1H, d, J = 15.50 Hz, H-2); 5.05 (1H, s, OH); 4.67 (2H, s, H-2'a, H-2'b), 3.95-3.94 (2H, m, H-1”a, H-1”b); 3.70-3.69 (2H, m, H-2”a, H-2”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.58, 146.14, 135.88, 132.37, 132.00, 131.92, 130.25, 129.33, 129.27, 129.13, 128.84, 123.07, 118.78, 117.51, 115.53, 67.51, 43.22, 31.15. ESI-MS m/z: 279.0946 [M+H]+.Yield: 59%. mp: 169-170℃. Rf = 0.37 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3383 (NH); 3217(OH); 2953, 2918 (CH, aren); 2851 (CH, CH 2 ); 1668 (C=O); 1599 (C=C). 1H-NMR (500 MHz, DMSO- d 6 ): δ 7.50 (1H, d, J = 15.50 Hz, H-3); 7.40 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.40 (1H, d, J = 15.50 Hz, H-2); 5.05 (1H, s, OH); 4.67 (2H, s, H-2'a, H-2'b), 3.95-3.94 (2H, m, H-1”a, H-1”b); 3.70-3.69 (2H, m, H-2”a, H-2”b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.58, 146.14, 135.88, 132.37, 132.00, 131.92, 130.25, 129.33, 129.27, 129.13, 128.84, 123.07, 1 18.78, 117.51, 115.53, 67.51, 43.22, 31.15 . ESI-MS m/z: 279.0946 [M+H] + .
화합물 4d: (E)-N-히드록시-3-(3-옥소-4-프로필-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)아크릴아미드Compound 4d: (E)-N-hydroxy-3-(3-oxo-4-propyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamide
수율: 61%. mp: 172-173 ℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3188 (OH); 2963, 2932 (CH, aren); 2876 (CH, CH2); 1665 (C=O); 1605 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 7.50 (1H, d, J = 15.50 Hz, H-3); 7.41 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.03 (1H, d, J = 8.00 Hz, H-8'); 6.42 (1H, d, J = 15.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b), 3.91-3.89 (2H, m, H-1”a, H-1”b); 1.61-1.59 (2H, m, H-2”a, H-2”b); 0.93-0.90 (2H, m, H-3”a, H-3”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.06, 163.33, 146.30, 138.27, 130.29, 129.39, 129.02, 127.92, 122.61, 118.45, 117.57, 115.61, 67.46, 42.06, 20.37, 11.44. ESI-MS m/z: 275.1041 [M-H]-.Yield: 61%. mp: 172-173℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3188 (OH); 2963, 2932 (CH, aren); 2876 (CH, CH 2 ); 1665 (C=O); 1605 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 7.50 (1H, d, J = 15.50 Hz, H-3); 7.41 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.03 (1H, d, J = 8.00 Hz, H-8'); 6.42 (1H, d, J = 15.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b), 3.91-3.89 (2H, m, H-1”a, H-1”b); 1.61-1.59 (2H, m, H-2”a, H-2”b); 0.93-0.90 (2H, m, H-3”a, H-3”b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.06, 163.33, 146.30, 138.27, 130.29, 129.39, 129.02, 127.92, 122.61, 118.45, 117.57, 115.61, 6 7.46, 42.06, 20.37, 11.44. ESI-MS m/z: 275.1041 [MH] - .
화합물 4e: (E)-3-(4-부틸-3-옥소-3,4-디히드로-2H-벤조[b][ 1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 4e: (E)-3-(4-butyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide
수율: 61%. mp: 168-169 ℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3175 (OH); 2920 (CH, aren); 2851 (CH, CH2); 1676, 1659 (C=O); 1601 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.72 (1H, s, NH); 9.02 (1H, s, OH); 7.50 (1H, d, J = 15.50 Hz, H-3); 7.40 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.03 (1H, d, J = 8.50 Hz, H-8'); 6.40 (1H, d, J = 15.50 Hz, H-2); 4.67 (2H, s, H-2'a, H-2'b), 3.95 (2H, t, J = 6.75 Hz, H-1”a, H-1”b); 1.57-1.54 (2H, m, H-2”a, H-2”b); 1.37-1.32 (2H, m, H-3”a, H-3”b); 0.94-0.91 (2H, m, H-4”a, H-4”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.02, 163.40, 146.35, 138.42, 130.24, 129.00, 122.62, 118.40, 117.58, 115.59, 67.47, 29.17, 19.89, 14.15. ESI-MS m/z: 289.1198 [M-H]-.Yield: 61%. mp: 168-169℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3175 (OH); 2920 (CH, aren); 2851 (CH, CH 2 ); 1676, 1659 (C=O); 1601 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.72 (1H, s, NH); 9.02 (1H, s, OH); 7.50 (1H, d, J = 15.50 Hz, H-3); 7.40 (1H, s, H-5'); 7.25 (1H, d, J = 7.50 Hz, H-7'); 7.03 (1H, d, J = 8.50 Hz, H-8'); 6.40 (1H, d, J = 15.50 Hz, H-2); 4.67 (2H, s, H-2'a, H-2'b), 3.95 (2H, t, J = 6.75 Hz, H-1”a, H-1”b); 1.57-1.54 (2H, m, H-2”a, H-2”b); 1.37-1.32 (2H, m, H-3”a, H-3”b); 0.94-0.91 (2H, m, H-4”a, H-4”b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.02, 163.40, 146.35, 138.42, 130.24, 129.00, 122.62, 118.40, 117.58, 115.59, 67.47, 29.17, 19. 89, 14.15. ESI-MS m/z: 289.1198 [MH] - .
화합물 4f: (E)-3-(4-(시클로프로필메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 4f: (E)-3-(4-(cyclopropylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N- Hydroxyacrylamide
수율: 64%. mp: 173-174 ℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3202 (OH); 2918 (CH, aren); 2851 (CH, CH2); 1680 (C=O); 1601 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 7.47 (1H, s, H-5'); 7.44 (1H, d, J = 16.50 Hz, H-3); 7.22 (1H, d, J = 7.00 Hz, H-7'); 7.01 (1H, d, J = 7.50 Hz, H-8'); 6.42 (1H, d, J = 15.50 Hz, H-2); 4.66 (2H, s, H-2'a, H-2'b), 3.86 (2H, d, J = 6.00 Hz, CH2); 1.14-1.12 (1H, m, H-1”); 0.55-0.46 (4H, m, H-2”a, H-2”b, H-3”a, H-3”b). 13C-NMR (125 MHz, DMSO-d6): δ 164.17, 146.19, 131.99, 130.38, 129.25, 129.19, 122.92, 118.68, 117.54, 115.52, 67.44, 44.46, 31.15. ESI-MS m/z: 287.1042 [M-H]-.Yield: 64%. mp: 173-174℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3202 (OH); 2918 (CH, aren); 2851 (CH, CH 2 ); 1680 (C=O); 1601 (C=C). 1H-NMR (500 MHz, DMSO- d 6 ): δ 7.47 (1H, s, H-5'); 7.44 (1H, d, J = 16.50 Hz, H-3); 7.22 (1H, d, J = 7.00 Hz, H-7'); 7.01 (1H, d, J = 7.50 Hz, H-8'); 6.42 (1H, d, J = 15.50 Hz, H-2); 4.66 (2H, s, H-2'a, H-2'b), 3.86 (2H, d, J = 6.00 Hz, CH 2 ); 1.14-1.12 (1H, m, H-1”); 0.55-0.46 (4H, m, H-2”a, H-2”b, H-3”a, H-3”b). 13 C-NMR (125 MHz, DMSO-d6): δ 164.17, 146.19, 131.99, 130.38, 129.25, 129.19, 122.92, 118.68, 117.54, 115.52, 67.44, 44.46, 31.1 5. ESI-MS m/z: 287.1042 [MH] - .
화합물 4g: (E)-3-(4-(시클로부틸메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 4g: (E)-3-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N- Hydroxyacrylamide
수율: 61%. mp: 180-181 ℃. Rf = 0.42 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3202 (OH); 2974, 2934 (CH, aren); 2855 (CH, CH2); 1672 (C=O); 1603 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 7.46 (1H, d, J = 16.00 Hz, H-3); 7.42 (1H, s, H-5'); 7.24 (1H, d, J = 8.00 Hz, H-7'); 7.03 (1H, d, J = 8.50 Hz, H-8'); 6.54 (1H, d, J = 16.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b), 4.05 (2H, d, J = 7.00 Hz, CH2); 2.66-2.63 (1H, m, H-1”); 1.96-1.74 (6H, m, H-2”a, H-2”b, H-3”a, H-3”b, H-4”a, H-4”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.40, 146.31, 138.73, 131.92, 129.20, 122.72, 118.42, 117.57, 115.91, 67.44, 44.86, 33.67, 33.62, 26.18, 18.34. ESI-MS m/z: 301.1198 [M-H]-.Yield: 61%. mp: 180-181℃. Rf = 0.42 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3202 (OH); 2974, 2934 (CH, aren); 2855 (CH, CH 2 ); 1672 (C=O); 1603 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 7.46 (1H, d, J = 16.00 Hz, H-3); 7.42 (1H, s, H-5'); 7.24 (1H, d, J = 8.00 Hz, H-7'); 7.03 (1H, d, J = 8.50 Hz, H-8'); 6.54 (1H, d, J = 16.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b), 4.05 (2H, d, J = 7.00 Hz, CH 2 ); 2.66-2.63 (1H, m, H-1”); 1.96-1.74 (6H, m, H-2”a, H-2”b, H-3”a, H-3”b, H-4”a, H-4”b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.40, 146.31, 138.73, 131.92, 129.20, 122.72, 118.42, 117.57, 115.91, 67.44, 44.86, 33.67, 33.6 2, 26.18, 18.34. ESI-MS m/z: 301.1198 [MH] - .
화합물 4h: (E)-3-(4-(시클로펜틸메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 4h: (E)-3-(4-(cyclopentylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N- Hydroxyacrylamide
수율: 64%. mp: 187-188 ℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3202 (OH); 2918 (CH, aren); 2853 (CH, CH2); 1672 (C=O); 1603, 1589 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.72 (1H, s, NH); 9.01 (1H, s, OH); 7.50 (1H, d, J = 15.50 Hz, H-3); 7.46 (1H, s, H-5'); 7.25 (1H, d, J = 8.00 Hz, H-7'); 7.04 (1H, d, J = 8.00 Hz, H-8'); 6.40 (1H, d, J = 16.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b); 3.94 (2H, d, J = 8.00 Hz, CH2); 2.26-2.23 (1H, m, H-1”); 1.63-1.24 (8H, m, H-2”a, H-2”b, H-3”a, H-3”b, H-4”a, H-4”b, H-5”a, H-5”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.40, 146.46, 138.42, 131.17, 129.08, 122.60, 118.40, 117.64, 115.99, 67.48, 55.37, 44.26, 37.83, 30.08, 24.83. ESI-MS m/z: 317.1508 [M+H]+.Yield: 64%. mp: 187-188℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3202 (OH); 2918 (CH, aren); 2853 (CH, CH 2 ); 1672 (C=O); 1603, 1589 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.72 (1H, s, NH); 9.01 (1H, s, OH); 7.50 (1H, d, J = 15.50 Hz, H-3); 7.46 (1H, s, H-5'); 7.25 (1H, d, J = 8.00 Hz, H-7'); 7.04 (1H, d, J = 8.00 Hz, H-8'); 6.40 (1H, d, J = 16.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b); 3.94 (2H, d, J = 8.00 Hz, CH 2 ); 2.26-2.23 (1H, m, H-1”); 1.63-1.24 (8H, m, H-2”a, H-2”b, H-3”a, H-3”b, H-4”a, H-4”b, H-5”a, H-5”b). 13C-NMR (125 MHz, DMSO- d 6 ): δ 164.40, 146.46, 138.42, 131.17, 129.08, 122.60, 118.40, 117.64, 115.99, 67.48, 55.37, 44.26, 37.8 3, 30.08, 24.83. ESI-MS m/z: 317.1508 [M+H] + .
화합물 4i: (E)-3-(4-(시클로헥실메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 4i: (E)-3-(4-(cyclohexylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N- Hydroxyacrylamide
수율: 66%. mp: 193-194 ℃. Rf = 0.45 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3200 (OH); 2922 (CH, aren); 2851 (CH, CH2); 1670 (C=O); 1603 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.73 (1H, s, NH); 9.02 (1H, s, OH); 7.51 (1H, d, J = 16.00 Hz, H-3); 7.43 (1H, s, H-5'); 7.25 (1H, d, J = 8.00 Hz, H-7'); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.39 (1H, d, J = 16.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b); 3.84 (2H, d, J = 7.00 Hz, CH2), 1.65-1.14 (11H, m, H-1”, H-2”a, H-2”b, H-3”a, H-3”b, H-4”a, H-4”b, H-5”a, H-5”b, H-6”a, H-6”b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.37, 163.42, 146.38, 138.49, 130.17, 129.39, 129.32, 122.38, 118.37, 117.65, 116.21, 67.46, 55.36, 45.78, 35.53, 30.45, 26.36, 25.70. ESI-MS m/z: 329.1520 [M-H]-.Yield: 66%. mp: 193-194℃. Rf = 0.45 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3200 (OH); 2922 (CH, aren); 2851 (CH, CH 2 ); 1670 (C=O); 1603 (C=C). 1H-NMR (500 MHz, DMSO- d 6 ): δ 10.73 (1H, s, NH); 9.02 (1H, s, OH); 7.51 (1H, d, J = 16.00 Hz, H-3); 7.43 (1H, s, H-5'); 7.25 (1H, d, J = 8.00 Hz, H-7'); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.39 (1H, d, J = 16.00 Hz, H-2); 4.68 (2H, s, H-2'a, H-2'b); 3.84 (2H, d, J = 7.00 Hz, CH 2 ), 1.65-1.14 (11H, m, H-1”, H-2”a, H-2”b, H-3”a, H-3” b, H-4”a, H-4”b, H-5”a, H-5”b, H-6”a, H-6”b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.37, 163.42, 146.38, 138.49, 130.17, 129.39, 129.32, 122.38, 118.37, 117.65, 116.21, 67.46, 55 .36, 45.78, 35.53, 30.45, 26.36, 25.70 . ESI-MS m/z: 329.1520 [MH] - .
실시예 2. 벤질을 포함하는 N-히드록시프로펜아미드 화합물의 제조 Example 2. Preparation of N-hydroxypropenamide compound containing benzyl
상기 실시예 1에서 알킬 브로마이드 대신 벤질 브로마이드 유도체를 사용한 것을 제외하고는 동일한 방법을 사용하여 목적 화합물 (화합물 7a-g)을 합성하였다(도 3).The target compounds (compounds 7a-g) were synthesized using the same method as in Example 1, except that a benzyl bromide derivative was used instead of alkyl bromide (FIG. 3).
화합물 7a: (E)-3-(4-벤질-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드Compound 7a: (E)-3-(4-benzyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide
수율: 65%. mp: 188-189 ℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3233 (OH); 2988 (CH, aren); 2853 (CH, CH2); 1647 (C=O); 1614, 1593 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.72 (1H, s, NH); 8.99 (1H, s, OH); 7.37-7.21 (8H, m, H-3, H-5', H-7', H-2”, H-3”, H-4”, H-5”, H-6”); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.27 (1H, d, J = 15.50 Hz, H-2); 5.21 (2H, s, CH2); 4.84 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.53, 163.26, 146.37, 138.17, 136.77, 129.91, 129.17, 129.01, 127.75, 127.33, 123.14, 118.37, 117.53, 115.80, 67.52, 43.80. ESI-MS m/z: 323.1032 [M-H]-.Yield: 65%. mp: 188-189℃. Rf = 0.41 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3233 (OH); 2988 (CH, aren); 2853 (CH, CH 2 ); 1647 (C=O); 1614, 1593 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.72 (1H, s, NH); 8.99 (1H, s, OH); 7.37-7.21 (8H, m, H-3, H-5', H-7', H-2”, H-3”, H-4”, H-5”, H-6”); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.27 (1H, d, J = 15.50 Hz, H-2); 5.21 (2H, s, CH2); 4.84 (2H, s, H-2'a, H-2'b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.53, 163.26, 146.37, 138.17, 136.77, 129.91, 129.17, 129.01, 127.75, 127.33, 123.14, 118.37, 1 17.53, 115.80, 67.52, 43.80. ESI-MS m/z: 323.1032 [MH] - .
화합물 7b: (E)-3-(4-(2-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드Compound 7b: (E)-3-(4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)- N-Hydroxyacrylamide
수율: 68%. mp: 195-196 ℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3240 (OH); 2918 (CH, aren); 2851 (CH, CH2); 1649 (C=O); 1618, 1589 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.73 (1H, s, NH); 9.00 (1H, s, OH); 7.36-7.21 (6H, m , H-3, H-5', H-7', H-3”, H-4”, H-6”); 7.15 (1H, t, J = 7.25 Hz, H-5”); 7.06 (1H, d, J = 8.50 Hz, H-8'), 6.28 (1H, d, J = 15.50 Hz, H-2); 5.24 (2H, s, CH2); 4.84 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.61, 163.24, 161.51, 159.56, 146.43, 138.14, 130.08, 129.88, 129.82, 129.40, 129.05, 128.89, 125.13, 125.11, 123.45, 123.40, 123.34, 118.44, 117.62, 116.06, 115.90, 115.37, 67.58. ESI-MS m/z: 341.0937 [M-H]-.Yield: 68%. mp: 195-196℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3240 (OH); 2918 (CH, aren); 2851 (CH, CH 2 ); 1649 (C=O); 1618, 1589 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.73 (1H, s, NH); 9.00 (1H, s, OH); 7.36-7.21 (6H, m , H-3, H-5', H-7', H-3”, H-4”, H-6”); 7.15 (1H, t, J = 7.25 Hz, H-5”); 7.06 (1H, d, J = 8.50 Hz, H-8'), 6.28 (1H, d, J = 15.50 Hz, H-2); 5.24 (2H, s, CH 2 ); 4.84 (2H, s, H-2'a, H-2'b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.61, 163.24, 161.51, 159.56, 146.43, 138.14, 130.08, 129.88, 129.82, 129.40, 129.05, 128.89, 1 25.13, 125.11, 123.45, 123.40, 123.34, 118.44 , 117.62, 116.06, 115.90, 115.37, 67.58. ESI-MS m/z: 341.0937 [MH] - .
화합물 7c: (E)-3-(4-(3-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 7c: (E)-3-(4-(3-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-yl)- N-Hydroxyacrylamide
수율: 66%. mp: 197-198 ℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3235 (OH); 2920 (CH, aren); 2851 (CH, CH2); 1649 (C=O); 1612, 1589 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.71 (1H, s, NH); 8.99 (1H, s, OH); 7.43-7.05 (8H, m, H-3, H-5', H-7', H-8', H-2”, H-4”, H-5”, H-6”); 6.28 (1H, d, J = 16.00 Hz, H-2); 5.22 (2H, s, CH2); 4.86 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.62, 163.82, 163.28, 161.88, 146.33, 139.81, 139.76, 138.15, 131.20, 131.13, 129.98, 128.95, 123.26, 123.24, 123.07, 118.42, 117.58, 115.80, 114.70, 114.53, 114.18, 114.00, 67.51, 43.49. ESI-MS m/z: 341.0943 [M-H]-.Yield: 66%. mp: 197-198℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3235 (OH); 2920 (CH, aren); 2851 (CH, CH 2 ); 1649 (C=O); 1612, 1589 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.71 (1H, s, NH); 8.99 (1H, s, OH); 7.43-7.05 (8H, m, H-3, H-5', H-7', H-8', H-2”, H-4”, H-5”, H-6”); 6.28 (1H, d, J = 16.00 Hz, H-2); 5.22 (2H, s, CH2); 4.86 (2H, s, H-2'a, H-2'b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.62, 163.82, 163.28, 161.88, 146.33, 139.81, 139.76, 138.15, 131.20, 131.13, 129.98, 128.95, 1 23.26, 123.24, 123.07, 118.42, 117.58, 115.80 , 114.70, 114.53, 114.18, 114.00, 67.51, 43.49. ESI-MS m/z: 341.0943 [MH] - .
화합물 7d: (E)-3-(4-(4-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 7d: (E)-3-(4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-yl)- N-Hydroxyacrylamide
수율: 69%. mp: 194-195 ℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3300 (NH); 3183 (OH); 2992 (CH, aren); 2762 (CH, CH2); 1643 (C=O); 1599, 1558 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.71 (1H, s, NH); 8.99 (1H, s, OH); 7.41-7.16 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.04 (1H, d, J = 8.00 Hz, H-8'); 6.28 (1H, d, J = 16.00 Hz, H-2); 5.19 (2H, s, CH2); 4.84 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.55, 163.28, 162.78, 160.85, 146.35, 138.18, 132.98, 132.95, 129.96, 129.51, 129.44, 129.40, 128.88, 123.13, 118.41, 117.55, 116.05, 115.88, 115.79, 67.51, 43.13. ESI-MS m/z: 341.0945 [M-H]-.Yield: 69%. mp: 194-195℃. Rf = 0.44 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3300 (NH); 3183(OH); 2992 (CH, aren); 2762 (CH, CH 2 ); 1643 (C=O); 1599, 1558 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.71 (1H, s, NH); 8.99 (1H, s, OH); 7.41-7.16 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.04 (1H, d, J = 8.00 Hz, H-8'); 6.28 (1H, d, J = 16.00 Hz, H-2); 5.19 (2H, s, CH 2 ); 4.84 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO- d 6 ): δ 164.55, 163.28, 162.78, 160.85, 146.35, 138.18, 132.98, 132.95, 129.96, 129.51, 129.44, 129.40, 1 28.88, 123.13, 118.41, 117.55, 116.05, 115.88, 115.79, 67.51, 43.13. ESI-MS m/z: 341.0945 [MH] - .
화합물 7e: (E)-3-(4-(4-클로로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 7e: (E)-3-(4-(4-chlorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N -Hydroxyacrylamide
수율: 71%. mp: 210-211 ℃. Rf = 0.46 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3300 (NH); 3183 (OH); 2992 (CH, aren); 1643 (C=O); 1599, 1558 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.71 (1H, s, NH); 8.99 (1H, s, OH); 7.43-7.22 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.05 (1H, d, J = 8.50 Hz, H-8'); 6.28 (1H, d, J = 15.50 Hz, H-2); 5.20 (2H, s, CH2); 4.84 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.56, 163.26, 146.33, 138.13, 135.88, 132.36, 130.00, 129.31, 129.13, 128.87, 123.15, 118.44, 117.57, 115.75, 67.51, 43.23. ESI-MS m/z: 357.0652 (35Cl), 359.0632 (37Cl) [M-H]-.Yield: 71%. mp: 210-211℃. Rf = 0.46 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3300 (NH); 3183(OH); 2992 (CH, aren); 1643 (C=O); 1599, 1558 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.71 (1H, s, NH); 8.99 (1H, s, OH); 7.43-7.22 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.05 (1H, d, J = 8.50 Hz, H-8'); 6.28 (1H, d, J = 15.50 Hz, H-2); 5.20 (2H, s, CH 2 ); 4.84 (2H, s, H-2'a, H-2'b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.56, 163.26, 146.33, 138.13, 135.88, 132.36, 130.00, 129.31, 129.13, 128.87, 123.15, 118.44, 1 17.57, 115.75, 67.51, 43.23. ESI-MS m/z: 357.0652 ( 35 Cl), 359.0632 ( 37 Cl) [MH] - .
화합물 7f: (E)-3-(4-(4-브로모벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)-N-히드록시아크릴아미드Compound 7f: (E)-3-(4-(4-bromobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)- N-Hydroxyacrylamide
수율: 73%. mp: 223-224 ℃. Rf = 0.47 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3296 (NH); 3183 (OH); 2992 (CH, aren); 1643 (C=O); 1599 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.72 (1H, s, NH); 9.01 (1H, s, OH); 7.55-7.22 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.28 (1H, d, J = 15.50 Hz, H-2); 5.18 (2H, s, CH2); 4.84 (2H, s, H-2'a, H-2'b). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.57, 163.28, 146.33, 138.17, 136.29, 132.04, 129.98, 129.65, 129.40, 128.85, 123.20, 120.85, 118.42, 117.58, 115.72, 67.50, 43.28. ESI-MS m/z: 401.0139 (79Br), 403.1024 (81Br) [M-H]-.Yield: 73%. mp: 223-224℃. Rf = 0.47 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3296 (NH); 3183(OH); 2992 (CH, aren); 1643 (C=O); 1599 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.72 (1H, s, NH); 9.01 (1H, s, OH); 7.55-7.22 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.04 (1H, d, J = 8.50 Hz, H-8'); 6.28 (1H, d, J = 15.50 Hz, H-2); 5.18 (2H, s, CH 2 ); 4.84 (2H, s, H-2'a, H-2'b). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.57, 163.28, 146.33, 138.17, 136.29, 132.04, 129.98, 129.65, 129.40, 128.85, 123.20, 120.85, 1 18.42, 117.58, 115.72, 67.50, 43.28. ESI-MS m/z: 401.0139 ( 79 Br), 403.1024 ( 81 Br) [MH] - .
화합물 7g: (E)-N-히드록시-3-(4-(4-메틸벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진 -6-일)아크릴아미드Compound 7g: (E)-N-hydroxy-3-(4-(4-methylbenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6 -1) Acrylamide
수율: 65%. mp: 188-189 ℃. Rf = 0.43 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ): 3291 (NH); 3221 (OH); 2959, 2918 (CH, aren); 2851 (CH, CH2); 1649 (C=O); 1601 (C=C). 1H-NMR (500 MHz, DMSO-d 6 ): δ 10.73 (1H, s, NH); 9.00 (1H, s, OH); 7.34-7.14 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.03 (1H, d, J = 8.50 Hz, H-8'); 6.28 (1H, d, J = 16.00 Hz, H-2); 5.16 (2H, s, CH2); 4.83 (2H, s, H-2'a, H-2'b), 2.26 (3H, s, 4”-CH3). 13C-NMR (125 MHz, DMSO-d 6 ): δ 164.48, 163.26, 146.38, 138.20, 136.92, 133.69, 129.87, 129.73, 128.96, 127.63, 123.10, 118.36, 117.49, 115.84, 67.52, 43.50, 21.12. ESI-MS m/z: 337.1210 [M-H]-.Yield: 65%. mp: 188-189℃. Rf = 0.43 (DCM/MeOH/AcOH = 90:5:1). IR (KBr, cm -1 ) : 3291 (NH); 3221 (OH); 2959, 2918 (CH, aren); 2851 (CH, CH 2 ); 1649 (C=O); 1601 (C=C). 1 H-NMR (500 MHz, DMSO- d 6 ): δ 10.73 (1H, s, NH); 9.00 (1H, s, OH); 7.34-7.14 (7H, m, H-3, H-5', H-7', H-2”, H-3”, H-5”, H-6”); 7.03 (1H, d, J = 8.50 Hz, H-8'); 6.28 (1H, d, J = 16.00 Hz, H-2); 5.16 (2H, s, CH 2 ); 4.83 (2H, s, H-2’a, H-2’b), 2.26 (3H, s, 4”-CH3). 13 C-NMR (125 MHz, DMSO- d 6 ): δ 164.48, 163.26, 146.38, 138.20, 136.92, 133.69, 129.87, 129.73, 128.96, 127.63, 123.10, 118.36, 1 17.49, 115.84, 67.52, 43.50, 21.12. ESI-MS m/z: 337.1210 [MH] - .
<실험예><Experimental example>
실험예 1. 세포독성 분석Experimental Example 1. Cytotoxicity analysis
상기 실시예 1 및 2에서 제조된 화합물들을 SW620(결장암), PC3(전립선암) 및 MDA-MB-231(유방암)을 포함한 3가지 인간 암 세포주에 처리하여 암 세포주에 대한 세포독성을 평가하였다. 세포주는 한국생명공학연구원(KRIBB) 암 세포 은행에서 구입하였다. 이 분석에서 세포 배양에 사용된 배지, 혈청 및 기타 시약은 GIBCO Co. Ltd. (Grand Island, New York, USA)에서 입수하였다. 각 세포는 DMEM(Dulbecco's Modified Eagle Medium)에서 밀집상태(confluence)까지 배양하였으며, 각 세포를 트립신 처리하고 3 x 104 세포/mL로 현탁시켰다. 0일차에 180 μL로 현탁한 세포 현탁액을 96 웰 플레이트의 각 웰에 접종했다. 그 다음 플레이트를 5% CO2 배양기에서 37 ℃, 24시간 동안 배양하였다. 화합물은 초기에 디메틸 설폭사이드(DMSO)에 용해시키고 배양 배지로 적절한 농도로 희석하였다. 그 다음 준비한 각 화합물의 시료 20 μL를 세포 현탁액을 96 웰 플레이트의 각 웰에 첨가한 후, 플레이트를 48시간 동안 추가로 배양하였다. 화합물의 세포독성은 수정된 비색 분석법으로 측정하였다. IC50값은 Probits method를 사용하여 계산하였으며 세 가지 독립적인 측정값의 평균이다(SD ≤ 10%). 결과는 하기의 표 1에 나타내었다.The compounds prepared in Examples 1 and 2 were treated with three human cancer cell lines, including SW620 (colon cancer), PC3 (prostate cancer), and MDA-MB-231 (breast cancer), and cytotoxicity on cancer cell lines was evaluated. Cell lines were purchased from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Cancer Cell Bank. Media, serum, and other reagents used for cell culture in this assay were purchased from GIBCO Co. Ltd. (Grand Island, New York, USA). Each cell was cultured in DMEM (Dulbecco's Modified Eagle Medium) until confluence, and each cell was trypsinized and suspended at 3 x 10 4 cells/mL. On day 0, 180 μL of the cell suspension was inoculated into each well of a 96 well plate. The plate was then incubated in a 5% CO 2 incubator at 37°C for 24 hours. Compounds were initially dissolved in dimethyl sulfoxide (DMSO) and diluted to appropriate concentrations with culture medium. Then, 20 μL of the prepared sample of each compound was added to each well of the 96-well plate, and the plate was further cultured for 48 hours. The cytotoxicity of the compounds was measured by a modified colorimetric assay. IC 50 values were calculated using the Probits method and are the average of three independent measurements (SD ≤ 10%). The results are shown in Table 1 below.
RCH 2 - or
상기 표 1로부터 알 수 있듯이, 본 발명에 따른 화합물 4a 내지 4i 및 7a 내지 7g는 모두 SW620, PC3 및 MDA-MB-231 세포주의 생장을 유의적으로 억제시킬 수 있는 것으로 확인되었다. As can be seen from Table 1, it was confirmed that compounds 4a to 4i and 7a to 7g according to the present invention can significantly inhibit the growth of SW620, PC3 and MDA-MB-231 cell lines.
실험예 2. HDAC 효소활성 분석Experimental Example 2. HDAC enzyme activity analysis
HDAC 효소(헬라 세포 핵 추출물)는 Enzo Life Sciences Inc.(Farmingdale, New York, USA)에서 구입하였다. HDAC 효소 분석은 제조사의 지침에 따라 Fluorogenic HDAC Assay Kit(Enzo Life Sciences Inc.)를 사용하여 수행하였다. HDAC 효소는 HDAC 형광 기질의 존재 하에 37 ℃에서 30분 동안 비히클 또는 다양한 농도의 분석된 시료 또는 SAHA와 함께 배양시켰다. HDAC 분석 현상액을 첨가하고 VICTOR(PerkinElmer, Waltham, MA, USA)를 통해 360 nm에서 여기(excitation), 460 nm에서 방출(emission)로 설정하여 형광을 측정하였다. 측정된 활성값은 비히클 처리된 대조군 효소 활성에서 차감하였고, IC50값은 GraphPad Prism(GraphPad Software, San Diego, CA, USA)을 사용하여 계산하였다.HDAC enzyme (HeLa cell nuclear extract) was purchased from Enzo Life Sciences Inc. (Farmingdale, New York, USA). HDAC enzyme assay was performed using the Fluorogenic HDAC Assay Kit (Enzo Life Sciences Inc.) according to the manufacturer's instructions. HDAC enzyme was incubated with vehicle or various concentrations of the analyzed sample or SAHA for 30 min at 37°C in the presence of HDAC fluorescent substrate. HDAC analysis developer was added and fluorescence was measured using VICTOR (PerkinElmer, Waltham, MA, USA) with excitation set at 360 nm and emission set at 460 nm. The measured activity value was subtracted from the vehicle-treated control enzyme activity, and the IC 50 value was calculated using GraphPad Prism (GraphPad Software, San Diego, CA, USA).
SAHA는 양성 대조군으로 사용하였다. 결과는 하기의 표 2에 표시하였다.SAHA was used as a positive control. The results are shown in Table 2 below.
또는
RCH 2 -
or
MW
MW
LogP
LogP
(IC 50, mM)HDAC inhibition
(IC 50 ,mM)
상기 표 2에서 알 수 있는 바와 같이, 본 발명에 따른 화합물 4a 내지 4i 및 7a 내지 7g는 모두 우수한 HDAC 억제 활성을 나타내었으며, 그 중에서도 특히 7e 및 7f는 현저히 우수한 HDAC 억제 활성을 나타내는 것으로 확인되었다.As can be seen in Table 2, compounds 4a to 4i and 7a to 7g according to the present invention all showed excellent HDAC inhibitory activity, and among them, 7e and 7f were confirmed to show significantly excellent HDAC inhibitory activity.
실험예 3. 세포주기, 세포자멸(apoptosis) 및 세포형태 분석Experimental Example 3. Cell cycle, apoptosis and cell shape analysis
상기 실험예 1 및 2의 결과는 화합물 7f가 3가지 인간 암 세포주에서 가장 세포 독성이 강한 화합물임을 나타내었다. 이와 같은 놀라운 세포 독성으로 우리는 이 화합물을 선택하여 세포 주기와 세포 사멸(apoptosis)에 대한 영향을 분석하였다. The results of Experimental Examples 1 and 2 showed that compound 7f was the most cytotoxic compound in three human cancer cell lines. Due to this surprising cytotoxicity, we selected this compound to analyze its effects on cell cycle and apoptosis.
실험과정은 SW620 세포(인간 결장암)(2x105 세포)를 화합물 7f(5 μM) 또는 SAHA(5 μM)로 24시간 동안 처리했다. 수확된 세포를 RNase의 존재하에 propidium iodide(PI)로 염색한 다음 DNA 함량, 세포주기 및 세포사멸을 분석하였다(도 4, 도 5). UN: 미처리, VH: 비히클(DMSO. 0.05%). 세포형태는 20X 렌즈(A) 또는 40X 렌즈(B)가 있는 Biostation을 사용하여 세포를 촬영하였다(도 6).In the experimental procedure, SW620 cells (human colon cancer) (2x10 5 cells) were treated with compound 7f (5 μM) or SAHA (5 μM) for 24 hours. Harvested cells were stained with propidium iodide (PI) in the presence of RNase and then analyzed for DNA content, cell cycle, and apoptosis (Figures 4 and 5). UN: untreated, VH: vehicle (DMSO. 0.05%). Cell morphology was photographed using a Biostation with a 20X lens (A) or a 40X lens (B) (Figure 6).
그 결과, 화합물 7f는 SW620 세포를 G2/M기에 머무르게 하는 반면, SAHA는 SW620 세포를 S 및 G2/M기에 멈추게 하였다. 또한, SW620 세포에서 화합물 7f가 후기 세포자멸을 어느정도 증가시켰음을 확인하였다. 세포 형태학적으로는, 화합물 7f가 SAHA와 거의 유사한 방식으로 SW620 세포를 평평하게 하는 것을 확인하였다.As a result, compound 7f caused SW620 cells to stay in the G2/M phase, while SAHA stopped SW620 cells in the S and G2/M phases. In addition, it was confirmed that compound 7f increased late-stage apoptosis to some extent in SW620 cells. In terms of cell morphology, it was confirmed that compound 7f flattens SW620 cells in a manner almost similar to SAHA.
Claims (7)
[화학식 1]
[화학식 2]
상기 화학식 1에서, R은 수소, 치환 또는 비치환된 C1-C10 알킬, 치환 또는 비치환된 C1~C10 알케닐, 치환 또는 비치환된 C1~C10 알키닐, 치환 또는 비치환된 치환 또는 비치환된 C1~C30 시클로알킬 중 하나이고;
상기 화학식 2에서, R은 치환 또는 비치환된 C5~C30 아릴, 치환 또는 비치환된 아릴알킬, 치환 또는 비치환된 아릴알케닐, 치환 또는 비치환된 아릴알키닐 중 하나이며;
상기 치환은 하나 이상의 수소를 불소, 염소, 브롬 및 요오드와 같은 할로겐; 히드록시; 니트로; 시아노; 옥소(=O); 티옥소(=S); 아지도; 니트로소; 아미노; 히드라지노; 포르밀; 알킬; 알콕시; 아릴; 트리플루오로메틸, 트리브로모메틸, 트리클로로메틸 등과 같은 할로알킬 그룹으로 바꾼 것이다.
A compound represented by Formula 1 or Formula 2 below and its pharmaceutically acceptable salt, hydrate, solvate, or optical isomer.
[Formula 1]
[Formula 2]
In Formula 1, R is hydrogen, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 1 -C 10 alkenyl, substituted or unsubstituted C 1 -C 10 alkynyl, substituted or unsubstituted It is one of substituted or unsubstituted C 1 to C 30 cycloalkyl;
In Formula 2, R is one of substituted or unsubstituted C 5 to C 30 aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted arylalkenyl, or substituted or unsubstituted arylalkynyl;
The substitution involves replacing one or more hydrogens with halogens such as fluorine, chlorine, bromine and iodine; hydroxy; nitro; cyano; oxo (=O); Thioxo (=S); Azido; nitroso; Amino; hydrazino; formyl; alkyl; alkoxy; aryl; It is changed to haloalkyl groups such as trifluoromethyl, tribromomethyl, and trichloromethyl.
할로겐이 존재하는 경우, 상기 할로겐은 불소, 염소, 브롬 또는 요오드이며; 알킬 그룹이 존재하는 경우, 상기 알킬 그룹은 메틸, 에틸, n-프로필, 이소프로필, 부틸, 이소부틸, t-부틸, 펜틸, 헥실, 헵틸, 옥틸 또는 이의 치환된 것이며;
시클로알킬 그룹이 존재하는 경우, 상기 시클로알킬 그룹은 시클로프로필, 시클로부틸, 시클로펜틸, 시클로헥실, 시클로옥틸, 시클로헵틸, 퍼히드로나프틸, 아다만틸, 가교된 시클릭 그룹들 또는 스피로비시클릭 그룹들(spirobicyclic groups)이며;
아릴 그룹이 존재하는 경우, 상기 아릴 그룹은 페닐, 나프틸, 안트라세닐, 인다닐 또는 비페닐이며;
히드록시알킬 그룹이 존재하는 경우, 상기 히드록시알킬 그룹은 히드록시메틸 또는 히드록시에틸인 것을 특징으로 하는 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체.
According to paragraph 1,
If halogen is present, the halogen is fluorine, chlorine, bromine or iodine; If an alkyl group is present, the alkyl group is methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl or substituted thereof;
When present, the cycloalkyl group may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, perhydronaphthyl, adamantyl, bridged cyclic groups or spirobicyclic groups. are spirobicyclic groups;
If an aryl group is present, the aryl group is phenyl, naphthyl, anthracenyl, indanyl or biphenyl;
A compound and a pharmaceutically acceptable salt, hydrate, solvate, or optical isomer thereof, wherein, if a hydroxyalkyl group is present, the hydroxyalkyl group is hydroxymethyl or hydroxyethyl.
상기 화학식 1의 R은 에틸, 2-클로로에틸, 2-히드록시에틸, n-프로필, n-부틸, , , 또는 이고,
상기 화학식 2의 R은 , , , , , 또는 인 것을 특징으로 하는 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체.
According to paragraph 1,
R in Formula 1 is ethyl, 2-chloroethyl, 2-hydroxyethyl, n-propyl, n-butyl, , , or ego,
R in Formula 2 is , , , , , or A compound and a pharmaceutically acceptable salt, hydrate, solvate, or optical isomer thereof.
화학식 1 또는 화학식 2로 표시되는 화합물은 다음의 화합물 중 어느 하나인 것을 특징으로 하는 화합물 및 그의 약제학적으로 허용되는 염, 수화물, 용매화물, 또는 광학이성질체:
(E)-3-(4-에틸-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(클로로에틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-N-히드록시-3-(4-(히드록시메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)아크릴아미드;
(E)-N-히드록시-3-(3-옥소-4-프로필-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)아크릴아미드;
(E)-3-(4-부틸-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(시클로프로필메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(시클로부틸메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(시클로펜틸메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(시클로헥실메틸)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-벤질-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(2-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(3-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(4-플루오로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(4-클로로벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드;
(E)-3-(4-(4-브로모벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)-N-히드록시아크릴아미드; 및
(E)-N-히드록시-3-(4-(4-메틸벤질)-3-옥소-3,4-디히드로-2H-벤조[b][1,4]옥사진-6-일)아크릴아미드.
According to paragraph 1,
The compound represented by Formula 1 or Formula 2 is a compound characterized in that it is any one of the following compounds and a pharmaceutically acceptable salt, hydrate, solvate, or optical isomer thereof:
(E)-3-(4-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide;
(E)-3-(4-(chloroethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide ;
(E)-N-hydroxy-3-(4-(hydroxymethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylic amides;
(E)-N-hydroxy-3-(3-oxo-4-propyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)acrylamide;
(E)-3-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide;
(E)-3-(4-(cyclopropylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-(Cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-(cyclopentylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-(cyclohexylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacryl amides;
(E)-3-(4-benzyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxyacrylamide;
(E)-3-(4-(2-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide;
(E)-3-(4-(3-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide;
(E)-3-(4-(4-fluorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide;
(E)-3-(4-(4-chlorobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxy acrylamide;
(E)-3-(4-(4-bromobenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydride Roxyacrylamide; and
(E)-N-hydroxy-3-(4-(4-methylbenzyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl) Acrylamide.
상기 암은 유방암, 폐암, 위암, 간암, 혈액암, 뼈암, 췌장암, 결장암, 피부암, 두경부암, 피부 또는 안구 흑색종, 자궁육종, 난소암, 직장암, 항문암, 대장암, 난관암, 자궁내막암, 자궁경부암, 소장암, 내분비암, 갑상선암, 부갑상선암, 신장암, 연조직종양, 요도암, 전립선암, 기관지암, 또는 골수암인 것을 특징으로 하는 암의 예방 또는 치료용 약제학적 조성물.
According to clause 5,
The above cancers include breast cancer, lung cancer, stomach cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, colon cancer, skin cancer, head and neck cancer, skin or eye melanoma, uterine sarcoma, ovarian cancer, rectal cancer, anal cancer, colon cancer, fallopian tube cancer, and endometrium. A pharmaceutical composition for the prevention or treatment of cancer, characterized in that it is cancer, cervical cancer, small intestine cancer, endocrine cancer, thyroid cancer, parathyroid cancer, kidney cancer, soft tissue tumor, urethral cancer, prostate cancer, bronchial cancer, or bone marrow cancer.
상기 화합물은 히스톤 탈아세틸화효소(histone deacetylase)의 억제를 통해 히스톤의 아세틸화를 촉진하는 활성을 갖는 것을 특징으로 하는 암의 예방 또는 치료용 약제학적 조성물.
According to clause 5,
The compound is a pharmaceutical composition for preventing or treating cancer, characterized in that it has the activity of promoting histone acetylation through inhibition of histone deacetylase.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220055057A KR20230155310A (en) | 2022-05-03 | 2022-05-03 | Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220055057A KR20230155310A (en) | 2022-05-03 | 2022-05-03 | Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230155310A true KR20230155310A (en) | 2023-11-10 |
Family
ID=88742297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220055057A KR20230155310A (en) | 2022-05-03 | 2022-05-03 | Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230155310A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070043978A (en) | 2004-07-28 | 2007-04-26 | 얀센 파마슈티카 엔.브이. | Substituted propenyl piperazine derivatives as novel inhibitors of hitone deacetylase |
KR20090094383A (en) | 2006-12-19 | 2009-09-04 | 메틸진 인크. | Inhibitors of histone deacetylase and prodrugs thereof |
KR101261305B1 (en) | 2004-07-28 | 2013-05-08 | 얀센 파마슈티카 엔.브이. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
KR101536050B1 (en) | 2013-07-30 | 2015-07-13 | 충북대학교 산학협력단 | Novel Isatin-Based Hydroxamic Acids and Anti-Cancer Composition Comprising the Same As Active Ingredient |
-
2022
- 2022-05-03 KR KR1020220055057A patent/KR20230155310A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070043978A (en) | 2004-07-28 | 2007-04-26 | 얀센 파마슈티카 엔.브이. | Substituted propenyl piperazine derivatives as novel inhibitors of hitone deacetylase |
KR101261305B1 (en) | 2004-07-28 | 2013-05-08 | 얀센 파마슈티카 엔.브이. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
KR20090094383A (en) | 2006-12-19 | 2009-09-04 | 메틸진 인크. | Inhibitors of histone deacetylase and prodrugs thereof |
KR101536050B1 (en) | 2013-07-30 | 2015-07-13 | 충북대학교 산학협력단 | Novel Isatin-Based Hydroxamic Acids and Anti-Cancer Composition Comprising the Same As Active Ingredient |
Non-Patent Citations (34)
Title |
---|
Barbarotta L., Hurley K. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. J. Adv. Pract. Oncol., 2015, 6, 22-36. |
Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784. |
Bracker, T.U., Sommer, A., Fichtner, I., Faus, H., Haendler, B., Hess-Stumpp, H. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models. Int. J. Oncol., 2009, 35, 909-920. |
De Ruijter, A.J.M.; Gennip, A.H.V.; Caron, H.N.; Kemp, S.; Kuilenburg, A.B.P.V. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 2003, 370, 737-739. |
Dung, D.T.M., Dung, P.T.P., Oanh, D.T.K., Huong, T.T.L., Hai, P.T., Huong, L.T.T., Loi, V.D., Hahn, H., Han, B.W., Kim, J., Han, S.B., Nam, N.H. Novel 2-oxoin-3-substitutedindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents. Med. Chem. 2015, 11, 8, 725-735. |
Glaser, K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol., 2007, 74, 659-671. |
Guha, M. HDAC inhibitors still need a home run, despite recent approval. Nature Reviews Drug Dis. 2015, 14, 225-226. |
Hamm, C.A., Costa, F.F. Epinomes as therapeutic targets. Pharmacol Ther., 2015, 151, 72-86. |
Hieu, D.T., Anh, D.T.; Hai, P.T.; Huong, L.T.T.; Park, E.J.; Choi, E.J.; Kang, J.S.; Dung, P.T.P.; Han, S.B.; Nam, N.H. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Chem. Biodivers. 2018, 15 (6), e1800027. |
Hieu, D.T.; Anh, D.T.; Nguyen, V.T.; Hai, P.T.; Huong, L.T.T.; Thuan, N.T.; Park, E.J.; Ji, A.Y.; Kang, J.S.; Dung, P.T.P.; Kim, J.; Kang, J.S.; Vu, T.K.; Dung, P.T.P.; Han, S.B.; Nam, N.H. Quinazolin-4(3H)-one-based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Chem. Biodivers. 2019, 16 (4), e1800502. |
Hieu, D.T.; Anh, D.T.; Tuan, N.M.; Hai, P.T.; Huong, L.T.T.; Kim, J.; Kang, J.S.; Vu, T.K.; Dung, P.T.P.; Han, S.B.; Nam, N.H.; Hoa, N.D. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents. Bioorg. Chem. 2018, 76, 258-267. |
Huong, T.T.L., Dung, D.T.M., Dung, P.T.P., Huong, P.T., Vu, T.K., Hahn, H., Han, B.W., Kim J., Han, S.B., Nam, N.H. Novel 2-oxoindoline-based hydroxamic acids: Synthesis, cytotoxicity and inhibition of histone deacetylation. Tetrahedron Lett. 2015, 56, 6424-6429. |
Huong, T.T.L., Dung, T.T., Huan, N.V., Cuong, L.V., Hai, P.T., Huong, L.T.T., Kim, J., Kim, Y.G., Han, S.B., Nam, N.H. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. Bioorg Chem. 2017, 67, 160-169. |
Lauffer, B.E.; Mintzer, R.; Fong, R.; Mukund, S.; Tam, C.; Zilberleyb, I.; Flicke, B.; Ritscher, A.; Fedorowicz, G.; Vallero, R.; Ortwine, D.F.; Gunzner, J.; Modrusan, Z.; Neumann, L.; Koth, C.M.; Lupardus, P.J.; Kaminker, J.S.; Heise, C.E.; Steiner, P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability, J. Biol. Chem., 2013, 288, 26926-26943. |
Li, J.; Li, G.; Xu, X. Histone deacetylase inhibitors: an attractive strategy for cancer therapy. Curr. Med. Chem., 2013, 20, 1858-1886. |
MarvinSketch (2016) Version 6.5.1, ChemAxon LLC 14th floor, Cambridge Innovation Center, One Broadway Cambridge, MA 02142, http://www.chemaxon.com. |
Molecular Operating Environment (MOE) (2016) Version 2009.10, Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, http://www.chemcomp.com. |
Nam N.H., Hong D.H., You Y.J., Kim Y., Bang S.C., Kim H.M., Ahn B.Z. Synthesis and cytotoxicity of 2, 5-dihydroxychalcones and related compounds. Arch. Pharm. Res. 2004, 27 (6), 581 |
Nam, N.H., Lee, S., Ye, G., Sun, G., Parang, K. ATP phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Bioorg. Med. Chem. 2004, 12, 5753-5766. |
Nam, N.H.; Huong, T.L.; Dung, D.T.M.; Oanh, D.T.K.; Dung, P.T.P.; Kim, K.R.; Han, B.W.; Kim, Y.S.; Hong, J.T.; Han, S.B. Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. J. Enzyme Inhib. Med. Chem., 2014, 29, 611-618. |
Nam, N.H.; Huong, T.L.; Dung, D.T.M.; Oanh, D.T.K.; Dung, P.T.P.; Quyen, D.; Kim, K.R.; Han, B.W.; Kim, Y.S.; Hong, J.T.; Han, S.B. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Eur. J. Med. Chem., 2013, 70, 477-486. |
Oanh, D.T.K.; Hai, H.V.; Hue, V.T.M.; Park, S.H.,; Kim, H.J.; Han, B.W.; Kim, H.S.; Hong, J.T.; Han, S.B.; Nam, N.H. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents. Bioorg. Med. Chem. Lett., 2011, 21, 7509-7512. |
Peng, X., Liao, G., Sun, P., Yu, Z., Chen, J. An overview of HDAC inhibitors and their synthetic routes. Curr. Top. Med. Chem., 2019, 19, 1005-1040. |
Qiu T, Zhou L, Zhu W, Wang T, Wang J, Shu Y, Liu P. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol., 2013, 9, 255-269. |
Skehan, P.; Storeng, R.; Scudiero, D.; Monk, A.; MacMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd. M.R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst., 1990, 82, 1107-1112. |
Tung, T.T.; Oanh, D.T.; Dung, P.T.; Hue, V.T.; Park, S.H.; Han, B.W.; Kim, Y.; Hong, J.T.; Han, S.B.; Nam, N.H. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents. Med. Chem., 2013, 9, 1051-1057. |
Valente, S.; Mai, A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011-2013). Expert. Opin. Ther. Pat., 2014, 24, 401-415. |
Ververis, K.; Hiong, A.; Karagiannis, T.C.; Licciardi, P.V. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics, 2013, 7, 47-60. |
West, A.C.; Johnstone, R.W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest., 2014, 124, 30-39. |
Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Cancer Lett., 2009, 277, 8-21. |
Wu, L.; Smythe, A.M.; Stinson, S.F.; Mullendore, L.A.; Monks, A.; Scudiero, D.A.; Paull, K.D.; Koutsoukos, A.D.; Rubinstein, L.V.; Boyd, M.R.; Shoemaker, R.H. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res., 1992, 52, 3029-3034. |
Wu, R., Lu, Z., Cao, Z., Zhang, Y. Zinc Chelation with Hydroxamate in Histone Deacetylases Modulated by Water Access to the Linker Binding Channel, J. Am. Chem. Soc. 2011, 133, 6110-6113. |
Zhang, S.G., Liang, C.G., Zhang, W.H. Recent advances in indazole-containing derivatives: Synthesis and biological perspectives. Molecules, 2018, 23, 2783. |
Zwergel C1, Valente S, Jacob C, Mai A. Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opin. Drug Discov., 2015, 10, 599-613. |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4405602B2 (en) | Histone deacetylase inhibitor | |
US7449477B2 (en) | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) | |
ES2598530T3 (en) | New condensed heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors | |
CN108524482B (en) | Use of 2- (substituted phenylamino) benzoic acid FTO inhibitors for treating leukemia | |
EA012451B1 (en) | Novel amido-substituted hydroxy-6-phenylphenanthridines | |
Hieu et al. | Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4 (3H)-ones as histone deacetylase inhibitors and antitumor agents | |
TW201625620A (en) | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | |
Huan et al. | Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity | |
JP2017528460A (en) | Isoxazole carboxamides as irreversible SMYD inhibitors | |
KR102063286B1 (en) | Novel Hydroxamic Acid Incorporating Quinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Anticancer Composition Comprising the Same | |
KR102055369B1 (en) | Novel 3/4-((Substitutedbenzamidophenoxy)methyl)-N-hydroxybenzamides/propenamides and its use | |
KR101624344B1 (en) | Novel 3-Substituted-2-Oxoindoline-Based N-hydroxypropenamides Having Activity of Inhibiting Histone Deacetylase and Antitumor Composition Comprising the Same | |
KR20230155310A (en) | Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient | |
KR102000035B1 (en) | Novel hydroxamic acids or N-hydroxybenzamides Incorporating Quinazoline as Histone Deacetylase Inhibitors and Anticancer Composition Comprising the Same | |
KR20230155311A (en) | Novel N-hydroxypropenamide compound and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient | |
KR102330072B1 (en) | Novel Indirubin-based N-Hydroxybenzamides, N-Hydroxypropenamides and N-Hydroxyheptanamides and its use | |
WO2015004610A1 (en) | 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction | |
KR101900575B1 (en) | Novel Hydroxamic Acids and Uses Thereof | |
KR101900574B1 (en) | Novel N-hydroxybenzamide and Use Thereof | |
EP4013497B1 (en) | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions | |
KR102233956B1 (en) | 3,4-dihydro-4-oxoquinazoline-based acetohydrazides and an anticancer composition comprising the same as an active ingredient | |
US8785659B2 (en) | Method for the production of sulphonylpyrroles as HDAC inhibitors | |
KR101964810B1 (en) | Novel N-Hydroxybenzamides or N-Hydroxypropenamides Incorporating Quinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Anticancer Composition Comprising the Same | |
KR102295963B1 (en) | Novel hydroxamic acids bearing 2-benzamidooxazole/thiazole or 2-phenylsulfonamidothiazole and its use | |
KR102385742B1 (en) | Novel 4-Oxoquinazoline-Based N-Hydroxypropenamides and its use |